For the final installment of this series, we “flashback” to our April 2016 issue, which featured a study examining 30-day complications among commercially insured adults undergoing colonoscopy with and without anesthesia-assisted sedation using Marketscan data (2008-2011).

Several letters to the editor challenged the methods used in this systematic review/meta-analysis, such that this question remains largely unresolved. What is clear is that we continue to lack an adequate understanding of which patients are most likely to benefit from anesthesia-assisted sedation, whether due to increased risk of failing standard sedation or increased risk of complications with standard sedation. This lack of clarity, as manifested in poorly specified guidelines, has fueled likely inappropriate allocation of monitored anesthesia care to low risk-patients (driven by a complex interplay of patient, provider, organizational, and economic factors), which has contributed to ballooning health care costs

Megan A. Adams, MS, JD, MSc, is a clinical lecturer in the division of gastroenterology at the University of Michigan, a gastroenterologist at the Ann Arbor Mich, VA, and an investigator in the VA Ann Arbor Center for Clinical Management Research. She is an associate editor of GI & Hepatology News.

For the final installment of this series, we “flashback” to our April 2016 issue, which featured a study examining 30-day complications among commercially insured adults undergoing colonoscopy with and without anesthesia-assisted sedation using Marketscan data (2008-2011).

Several letters to the editor challenged the methods used in this systematic review/meta-analysis, such that this question remains largely unresolved. What is clear is that we continue to lack an adequate understanding of which patients are most likely to benefit from anesthesia-assisted sedation, whether due to increased risk of failing standard sedation or increased risk of complications with standard sedation. This lack of clarity, as manifested in poorly specified guidelines, has fueled likely inappropriate allocation of monitored anesthesia care to low risk-patients (driven by a complex interplay of patient, provider, organizational, and economic factors), which has contributed to ballooning health care costs

Megan A. Adams, MS, JD, MSc, is a clinical lecturer in the division of gastroenterology at the University of Michigan, a gastroenterologist at the Ann Arbor Mich, VA, and an investigator in the VA Ann Arbor Center for Clinical Management Research. She is an associate editor of GI & Hepatology News.

For the final installment of this series, we “flashback” to our April 2016 issue, which featured a study examining 30-day complications among commercially insured adults undergoing colonoscopy with and without anesthesia-assisted sedation using Marketscan data (2008-2011).

Several letters to the editor challenged the methods used in this systematic review/meta-analysis, such that this question remains largely unresolved. What is clear is that we continue to lack an adequate understanding of which patients are most likely to benefit from anesthesia-assisted sedation, whether due to increased risk of failing standard sedation or increased risk of complications with standard sedation. This lack of clarity, as manifested in poorly specified guidelines, has fueled likely inappropriate allocation of monitored anesthesia care to low risk-patients (driven by a complex interplay of patient, provider, organizational, and economic factors), which has contributed to ballooning health care costs

Megan A. Adams, MS, JD, MSc, is a clinical lecturer in the division of gastroenterology at the University of Michigan, a gastroenterologist at the Ann Arbor Mich, VA, and an investigator in the VA Ann Arbor Center for Clinical Management Research. She is an associate editor of GI & Hepatology News.

Oral semaglutide can achieve levels of glycemic control and weight loss similar to those of subcutaneous semaglutide, according to a phase 2, placebo-controlled trial published in the Oct. 17 edition of JAMA.

In a parallel-group, dosage-finding 26-week trial, 632 patients with type 2 diabetes and poor glycemic control were randomized to either 2.5 mg, 5 mg, 10 mg, 20 mg, or 40 mg of once-daily oral semaglutide escalated over 4 weeks (standard escalation); 40 mg escalated over 8 weeks; 40 mg escalated over 2 weeks; once-weekly subcutaneous semaglutide (1 mg) for 26 weeks, or oral placebo.

The study found that all patients who had received oral or subcutaneous semaglutide showed significantly reduced mean hemoglobin A_1c levels compared with placebo. Almost all patients treated with semaglutide – both oral and subcutaneous – showed a reduction in HbA_1c levels while only 74% of patients in the placebo group did (JAMA 2017 Oct 17;318[15]:1460-70. doi: 10.1001/jama.2017.14752).

The estimated treatment difference compared with placebo at week 26 ranged from –0.4% for the 2.5-mg group to –1.6% for the 40-mg-over-4-weeks group, and –1.6% for the subcutaneous group.

Oral semaglutide can achieve levels of glycemic control and weight loss similar to those of subcutaneous semaglutide, according to a phase 2, placebo-controlled trial published in the Oct. 17 edition of JAMA.

In a parallel-group, dosage-finding 26-week trial, 632 patients with type 2 diabetes and poor glycemic control were randomized to either 2.5 mg, 5 mg, 10 mg, 20 mg, or 40 mg of once-daily oral semaglutide escalated over 4 weeks (standard escalation); 40 mg escalated over 8 weeks; 40 mg escalated over 2 weeks; once-weekly subcutaneous semaglutide (1 mg) for 26 weeks, or oral placebo.

The study found that all patients who had received oral or subcutaneous semaglutide showed significantly reduced mean hemoglobin A_1c levels compared with placebo. Almost all patients treated with semaglutide – both oral and subcutaneous – showed a reduction in HbA_1c levels while only 74% of patients in the placebo group did (JAMA 2017 Oct 17;318[15]:1460-70. doi: 10.1001/jama.2017.14752).

The estimated treatment difference compared with placebo at week 26 ranged from –0.4% for the 2.5-mg group to –1.6% for the 40-mg-over-4-weeks group, and –1.6% for the subcutaneous group.

Oral semaglutide can achieve levels of glycemic control and weight loss similar to those of subcutaneous semaglutide, according to a phase 2, placebo-controlled trial published in the Oct. 17 edition of JAMA.

In a parallel-group, dosage-finding 26-week trial, 632 patients with type 2 diabetes and poor glycemic control were randomized to either 2.5 mg, 5 mg, 10 mg, 20 mg, or 40 mg of once-daily oral semaglutide escalated over 4 weeks (standard escalation); 40 mg escalated over 8 weeks; 40 mg escalated over 2 weeks; once-weekly subcutaneous semaglutide (1 mg) for 26 weeks, or oral placebo.

The study found that all patients who had received oral or subcutaneous semaglutide showed significantly reduced mean hemoglobin A_1c levels compared with placebo. Almost all patients treated with semaglutide – both oral and subcutaneous – showed a reduction in HbA_1c levels while only 74% of patients in the placebo group did (JAMA 2017 Oct 17;318[15]:1460-70. doi: 10.1001/jama.2017.14752).

The estimated treatment difference compared with placebo at week 26 ranged from –0.4% for the 2.5-mg group to –1.6% for the 40-mg-over-4-weeks group, and –1.6% for the subcutaneous group.

From UT Southwestern Medical Center, Dallas, TX.

Abstract

• Objective: To review the literature on and provide evidence-based recommendations for management of HIV/ hepatitis B (HBV) coinfection.
• Methods: Review of the literature for clinical trials, guidelines, and cohort studies on HIV/HBV disease management.
• Results: HIV patients should be evaluated for viral hepatitis. Those who do not have evidence of immunity should be vaccinated and monitored for response. Those who have HIV/HBV should have additional serologies checked to evaluate for hepatitis B e antigen status and level of viremia. All HIV/HBV coinfected patients should be started on antiretroviral therapy with tenofovir-based regimens. Those with HIV/HBV and cirrhosis should be screened for hepatocellular cancer every 6 months.
• Conclusion: HIV patients should be vaccinated against hepatitis B; those with coinfection should be treated for both viruses. It is important to monitor for treatment response to both HIV and HBV and liver disease complications.

Key words: incentives; reinforcement; substance abuse treatment; dissemination; implementation.

Morbidity and mortality for HIV-infected patients remain high compared to uninfected patients despite effective virologic suppression. Major contributors to illness and death among these patients include cardiovascular disease, non–AIDS-defining malignancies, and chronic liver disease, specifically viral hepatitis [1]. Hepatitis B virus (HBV) infection is one of the main causes of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) globally. Because HIV and HBV can both be acquired through injection drug use and sexual transmission, coinfection occurs frequently. The Joint United Nations Program on HIV/AIDS estimates that 10% of the 33 million HIV-positive patients worldwide have simultaneous chronic HBV infection [2].

HIV/HBV coinfection significantly impacts the natural history, progression, and mortality related to both viruses. HIV infection accelerates HBV-related liver impairment, leading to earlier cirrhosis, end-stage liver disease, and HCC. Conversely, chronic HBV does not have a considerable influence in the progression of HIV; however, antiretroviral treatment (ART) toxicities and/or HBV flares due to immune reconstitution inflammatory syndrome (IRIS) or HBV itself can lead to increased liver-related complications [3,4].

Case Patient 1

Initial Presentation and History

An asymptomatic 38-year-old man diagnosed with HIV infection 1 month ago presents for his initial visit to establish HIV care. The patient is a man who has sex with men (MSM) and is currently sexually active with multiple partners. He reports inconsistent use of condoms. One month ago he under­went routine screening and was found to be HIV-positive. At the time of diagnosis, the patient’s baseline CD4 cell count was 328 cells/µL and his viral load was 182,600 copies/mL. The patient wants to discuss the implications of his new diagnosis of HIV and recommendations for further testing and treatment. He is especially interested in HBV screening, since one of his recent partners was known to be positive. The patient has no relevant past medical history. He does not recall the details of his childhood vaccinations. He denies smoking and injection drug use but reports moderate alcohol consumption.

Physical Examination and Laboratory Testing

Physical examination is normal. Laboratory studies show normal complete blood count (CBC) and renal and liver function test results, and a baseline HIV genotype does not show resistance. Hepatitis A total antibody (anti-HAV) testing is positive, while tests for hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), and hepatitis C antibody (anti-HCV) are negative.

• Which screening tests for HBV should be performed in HIV-infected patients?

Routine screening of all HIV-infected patients for hepatitis A virus, HBV, and hepatitis C virus (HCV) is recommended [5]. Routine HBV screening involves obtaining serologies for HBsAg, anti-HBs, and anti-HBc. With these results, patients can be classified into categories of either active infection, immunity, or no evidence of prior exposure (Table 1).

• How effective is HBV vaccination in the HIV population?

Vaccination

Available HBV vaccines in the United States include 2 single-agent vaccines (Recombivax HB [Merck, Whitehouse Station, NJ] and Engerix-B [GlaxoSmithKline, Research Triangle Park, NC]) as well as a combination HAV/HBV vaccine (Twinrix [GlaxoSmithKline]). For adults (age ≥ 20 years) with an immunocompromising condition such as HIV infection, current Centers for Disease Control and Prevention guidelines recommend three 40 µg/mL doses of single-agent vaccine administered at 0, 1, and 6 months (Recombivax HB), or four 40 µg/mL doses of single-agent vaccine (2 doses of 20 µg/mL administered simultaneously) at 0, 1, 2, and 6 months (Engerix-B) [7].

The immunogenicity to HBV vaccination in HIV-positive patients is decreased, reflected by lower anti­body titers, waning immunity, and seroconversion rates of 18% to 65% [8–11]. Factors associated with poor response include low CD4 cell counts, detectable HIV RNA, coinfection with HCV, and the general health status of the patient [8]. Ideally, HBV vaccination should occur prior to decline in CD4 cell count below 350 cells/µL. However, guidelines do not recommend deferring vaccination since some patients with advanced HIV disease will seroconvert [6].

Anti-HBs titers should be checked 1 month after completion of the vaccine series to confirm protective antibody titers. For patients with quantitative anti-HBs levels < 10 IU/mL, a second vaccine cycle is recommended. Some specialists may defer revaccination until a sustained increase in CD4 count is achieved on ART.

Two randomized controlled trials have demonstrated that 4 doses of double-dose (40 µg/mL) vaccine generate higher anti-HBs levels than 3 doses of standard-dose (20 µg/mL) vaccine in HIV-infected adults [12,13]. Another study showed that HIV patients with CD4 counts > 350 cells/µL had better responses when immunized with double- dose vaccines on the usual 3-dose series [14]. Currently, the CDC recommends giving a double dose for either a 3-dose schedule or a 4-dose schedule. However, it remains unclear what dosing schedule to use if a patient fails to respond. Likely waiting until the CD4 cell count has increased and HIV viral load is suppressed will be important to seeing a response.

• What approach for HBV prevention should be taken in this patient?

The patient’s serologies confirm no prior exposure to HBV, and he should be offered HBV vaccination. His CD4 cell count is below 350/µL and he has ongoing HIV viremia, which increases his risk for an inadequate response. However, vaccination should not be delayed, particularly given his high risk of sexual transmission. The patient should be counseled regarding all high-risk behaviors. As discussed above, 3 or 4 doses of the higher dose vaccine (40 µg/mL) should be administered depending on what type of recombinant vaccine is available. An anti-HBs level should be checked 1 month after completion. A full repeat vaccine series using the 40 µg/mL dose should be considered for nonresponders who initially received a standard vaccine series. Experts also recommend checking annual anti-HBs levels to monitor for waning immunity, with a booster dose given if the anti-HBs level drops below the protective range.

• What vaccination strategy should be used in patients with isolated positive anti-HBc?

The clinical implications of an isolated positive anti-HBc for vaccination are still uncertain. This serologic pattern may represent a false-positive test, remote HBV infection with loss of anti-HBs, or occult HBV infection with undetectable HBsAg. The latter scenario appears more commonly in HIV-infected patients, particularly with concomitant HCV infection [15].

A recent study suggested that patients with an isolated positive anti-HBc with a negative anamnestic antibody response (anti-HBs titer of < 10 IU/mL 4 weeks after a single 20 µg dose of recombinant HBV vaccine) should be further vaccinated with the double-dose for a 3-dose schedule [6]. Additionally, another study followed HIV/HCV coinfected patients for 9.5 years and found that an isolated positive anti-HBc was not associated with accelerated liver disease progression [16].

Treatment of HIV-1 Infection

Current HIV guidelines recommend initiation of ART for all HIV-infected patients regardless of their CD4 count [17]. ART for a treatment-naïve patient usually consists of 2 nucleotide/nucleoside reverse-transcriptase inhibitors (NRTIs; the “backbone”) combined with a third agent (the “anchor”), which can be a nonnucleoside reverse-transcriptase inhibitor (NNRTI), a protease inhibitor (PI) boosted with a boosting agent, or an integrase strand-transfer inhibitor (INSTI) [18,19].

There are numerous studies indicating that incident HBV risk can be reduced by placing those at risk for HBV acquisition on ART containing a combination of tenofovir disoproxil fumarate (TDF), lamivudine, or emtricitabine [20,21]. Another study in MSM found those on ART with HIV viral load < 400 copies/mL were protected from developing HBV compared to those not on ART [22]. Given this patient’s higher risk for HBV acquisition, placing him on emtricitabine/TDF backbone as part of ART could be protective against incident HBV [23].

Case Patient 2

Initial Presentation and History

A 32-year-old man diagnosed with HIV infection 8 years ago now on ART presents for follow-up. The patient is an MSM with a history of inconsistent condom use. At the time of HIV diagnosis 8 years ago, the patient had a CD4 cell count of 250 cells/µL and an HIV viral load of 648,000 copies/mL. The patient was initiated on lamivudine/zidovudine and lopinavir/ritonavir, and he achieved complete virologic suppression at 20 weeks, with a CD4 cell count of 455 cells/µL at 1 year. The patient has remained on this regimen without major side effects; however, he reports frequent missed doses over the last 2 years due to “pill fatigue.” Previous testing for HBV and HCV at the time of his initial HIV diagnosis was negative, but he failed to complete the HBV vaccine series. He denies alcohol or injection drug use.

Physical Examination and Laboratory Testing

Physical examination is normal. Laboratory studies reveal normal electrolytes and renal function, hemoglobin of 11 g/dL, and platelet count of 235,000/µL. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels are 34 U/L and 44 U/L, respectively, with an INR of 1.1 and albumin level of 3.4 g/dL. CD4 cell count is 320 cells/µL with an HIV viral load of 24,500 copies/mL. Viral hepatitis serologies show anti-HAV positive, anti-HCV negative, HBsAg positive, anti-HBc IgG positive, hepatitis Be antigen (HBeAg) negative, and hepatitis B e antibody (anti-HBe) positive. HBV DNA viral load is 685,000 IU/mL.

• What is the natural history of HIV/HBV coinfection?

Chronic HBV infection affects about 10% of HIV-infected patients globally. Epidemiologic studies indicate that HIV-infected patients have higher rates of reactivation and progression to chronic HBV infection and chronic liver disease than HIV-negative patients [24–26]. Coinfected patients demonstrate higher serum HBV DNA levels, which lead to more rapid progression of hepatic fibrosis and may increase the risk of cirrhosis and HCC [24,27,28]. HIV infection, however, can mediate the necroinflammatory response through blunting of the immune response that drives pathogenesis in HBV infection. Aminotransferase levels may be only slightly elevated or even normal, particularly in the severely immune suppressed. However, elevation in liver enzymes (hepatitis flare) can occur if a patient stops ART, or if HBV resistance develops. Patients being treated for HIV/HBV coinfection should be counseled that stopping HIV treatment puts them at risk of developing a hepatitis flare.

Large cohort studies of HIV/HBV coinfected patients indicate increased risk of liver-related mortality, most pronounced with lower CD4 cell counts [1,28,29]. Introduction of ART appears to increase rather than attenuate this liver-related mortality, possibly by decreasing AIDS-related mortality and allowing more time for liver disease progression. Finally, a recent meta-analysis including 12,382 patients demonstrated a significant effect of HIV/HBV coinfection on all-cause mortality, with a pooled effect estimate of 1.36 [30].

• What diagnostic testing should be done in coinfected patients?

Diagnostic Testing and Evaluation

Persistence of HBsAg for more than 6 months is diagnostic of chronic HBV infection and warrants further serologic evaluation. Patients with chronic HBV infection should be tested for HBeAg, anti-HBe, and HBV DNA levels and have AST and ALT levels measured. Elevation of AST and ALT can be seen with untreated HBV. For those on treatment, a hepatitis flare could be caused by abrupt discontinuation of HBV treatment, development of HBV resistance, or superinfection with another viral pathogen.

HBeAg is a marker of active viral replication and is associated with higher levels of HBV DNA and active liver disease. Seroconversion, or loss of HBeAg and development of anti-HBe, heralds a favorable treatment response for those who were initially HBeAg-positive. However, some HBV variants have precore or core promoter mutations that lead to higher levels of HBV DNA in the absence of HBeAg. This highlights the importance of monitoring HBV DNA levels in all patients with chronic HBV infection. Favorable response to therapy in HBeAg-negative patients is marked by normalization of aminotransferases and HBV DNA suppression.Hepatitis D virus (HDV) is a defective virus particle that can only replicate in the presence of HBV. Coinfected patients should be tested for anti-HDV if they are injection drug users or are from a high-prevalence region such as the Mediterranean and Amazon basins. Newly acquired HDV infection should also be considered in the context of hepatitis flares.

Although these routine diagnostic tests are essential for management, studies show low adherence rates to HBV testing guidelines by HIV providers [31,32].

• What is the role of HBV genotype and resistance testing?

HBV can be classified into 10 different genotypes, A through J, based on genomic sequence variations. Each genotype has a distinct ethnic and geographic distribution, with genotypes A and D predominating in North America. HBV genotyping appears to have important prognostic as well as treatment implications [19]. However, data are still preliminary and the guidelines do not recommend routine genotype testing.

Resistance testing in HBV allows for detection of mutations that decrease effectiveness of antivirals. Exposure to lamivudine can lead to mutations in the YMDD region of the HBV DNA polymerase, resulting in drug resistance. Resistance to lamivudine develops at a rate of approximately 25% after 1 year of drug exposure in HIV/HBV coinfection [33]. On the other hand, studies have shown that entecavir is active against HIV and, most importantly, selects for the M184V mutation in HIV. M184V is associated with lamivudine resistance for HIV treatment, thus limiting treatment options [34,35]. After these findings, the FDA advised against monotherapy with entecavir in patients with HIV/HBV coinfection. The case patient was on lamivudine during the time of HBV acquisition, and therefore YMDD mutation must be taken into consideration for therapy purposes. He should be switched to a regimen that suppresses both viruses. The development of drug resistance should be assessed in all patients with persistent or breakthrough HBV viremia on ART, particularly the nucleoside analogues. HIV providers treating HIV/HBV coinfection should regularly monitor both HIV and HBV viral load to assess for therapeutic efficacy.

• What is the role of liver biopsy in this patient?

Liver biopsy should be considered in all coinfected patients as it remains the gold standard for determining the activity and severity of chronic hepatitis B. However, because it carries inherent risks and is not required prior to treatment in all patients, the decision should be individualized. Liver biopsy can be useful to assess baseline liver histology and may be warranted to rule out significant coexisting genetic or metabolic liver disease. Currently, noninvasive methods to assess liver fibrosis either using elastography or various combinations of serum biomarkers are being evaluated [36] and may be considered in lieu of a liver biopsy [37]. One study compared the accuracy of elastography with liver biopsy in HIV/HBV coinfected patients and demonstrated that the former was proficient in discriminating between absence or mild fibrosis and moderate to severe fibrosis [38]. In general, this test has high accuracy in detecting minimal fibrosis from advanced fibrosis or cirrhosis. For the group in the middle, further investigation with additional methods must be considered [37]. Finally, a recent retrospective study involving 70 HIV/HBV coinfected individuals showed fibrosis regression suggesting beneficial effects of long-term ART on liver stiffness, [39] but further studies are needed to confirm these findings.

Case 2 Continued

The patient has now been diagnosed with chronic HBV infection. His diagnostic testing is negative for HBeAg and reveals modest HBV viremia with abnormal aminotransferases less than 2 times the upper limit of normal. Drug resistance testing reveals a mutation in the YMDD region indicative of HBV lamivudine resistance. HIV genotype demonstrates a wild-type virus without resistance. The patient asks what treatment options exist.

• What medications are currently available to treat hepatitis B?

Treatment

All patients with HIV/HBV coinfection should receive treatment to suppress both viruses, and ART needs to include 2 drugs active against HBV, ideally emtricitabine and TDF. This approach prevents drug resistance, slows progression of HBV infection, and reduces the incidence of IRIS [5]. TDF has been associated with decreased renal function and bone mineral density. Recently, tenofovir alafenamide fumarate (TAF) was approved for the treatment of HIV and HBV. A dose of 10 mg daily is given when coadministered with ritonavir, cobicistat, or protease inhibitors, but a dose of 25 mg should be given when administered with NNRTIs or integrase inhibitors. Compared to TDF, TAF shows less accumulation of tenofovir in kidneys and bones and consequently has reduced renal and bone mineral density effects [40]. All patients should be on a TDF- or TAF-based HIV regimen if they have chronic HBV.

Currently, the following antiviral drugs are FDA-approved for the treatment of HBV infection: interferon alfa-2b, pegylated interferon (peginterferon) alfa-2a, lamivudine and emtricitabine, entecavir, adefovir, TDF, TAF, and telbivudine. Telbivudine and adefovir are no longer recommended due to their association with higher incidence of toxicity and higher rates of HBV treatment failure. A summary of available HBV treatment options is outlined in Table 2.

Interferon

Standard interferon alfa-2b blocks HBV replication through interaction with viral proteins and stimulation of host cellular immunity. Peginterferon alfa-2a has proven efficacy in HBV-monoinfected patients, but efficacy data in HIV/HBV coinfected patients is lacking [41,42]. Studies in hepatitis C treatment demonstrate the safety of peginterferon alfa-2a use in HIV-positive patients and indicate that HIV viral suppression occurs with peginterferon without evidence of selection of resistance mutations that affect future ART options [43]. For HIV/HBV coinfected patients not on ART who will receive only therapy for HBV (which is infrequent since all HIV patients should be on ART), pegylated interferon-alfa-2a alone for 48 weeks is the only option that will not cause ART-associated HIV drug resistance [5]. Interferon therapy is contraindicated in patients with decompensated cirrhosis and should be used with caution in patients with active depression, uncontrolled diabetes, and cardiac and pulmonary disease.

Lamivudine and Emtricitabine

Lamivudine is a nucleoside analogue with efficacy against both HIV and HBV. Clinical trials in HIV/HBV-infected patients have shown up to 87% of patients achieve undetectable HBV DNA levels and about 25% achieve HBeAg seroconversion after 1 to 2 years of therapy [44,45]. However, the major issue limiting use of lamivudine is its low genetic barrier to resistance. Mutation of the YMDD motif of the HBV DNA polymerase confers HBV resistance. HIV/HBV coinfected patients develop resistance at rates of up to 94% after 4 years of therapy [33], heralded by rebounds in HBV DNA levels and often hepatitis flares or precipitation of hepatic failure [16]. Because of resistance, lamivudine monotherapy should be avoided; even in patients on ART, abrupt withdrawal of lamivudine or the development of HBV resistance should be closely monitored.

Emtricitabine is another nucleoside analogue with properties and efficacy similar to lamivudine. It is frequently used as a combination pill with TDF (Truvada) in coinfected patients. The same concerns regarding monotherapy and the emergence of resistance that exist for lamivudine apply to emtricitabine.

Tenofovir

TDF, a nucleotide analogue, is one of the preferred first-line agents for HIV treatment and has proven efficacy against both wild-type and lamivudine-resistant HBV. Since it was first used for HIV, TDF has been more extensively studied in coinfected patients compared to most other agents. In a meta-analysis of patients with HIV/HBV coinfection, TDF suppressed HBV viral load to undetectable titers in approximately 90% of patients [46]. Tenofovir is available in 2 preparations: TDF and TAF. TDF has been reported to cause renal impairment as well as bone loss. TAF has shown less renal toxicity and less bone damage [40,47]. In 2016, TAF became available as part as 4 regimens: stand-alone TAF, elvitegravir-cobicistat-emtricitabine-TAF, rilpivirine-emtricitabine-TAF, and TAF-emtricitabine.

TDF and TAF both suppress HIV. Two large randomized trials of HBV monoinfection demonstrate that TAF is noninferior to TDF for the treatment of naïve and treatment-experienced patients [48,49].

Entecavir

Entecavir, a guanosine analogue, is a potent HBV DNA polymerase inhibitor that results in greater virologic suppression compared to lamivudine and retains activity against lamivudine-resistant HBV [50]. Importantly, entecavir shares some cross-resistance with lamivudine, so an entecavir dose of 1 mg daily is recommended in lamivudine-experienced patients compared to 0.5 mg daily in lamivudine-naïve patients. Entecavir requires dose reduction for patients with creatinine clearance less than 50 mL/min, although it is not associated with renal toxicity. A 1-log10 reduction in HIV RNA levels as well as emergence of M184V mutations on entecavir monotherapy has been reported [51,52]. M184V confers HIV resistance to lamivudine and emtricitabine. Therefore, entecavir should not be used as monotherapy in HIV-coinfected patients and/or patients with evidence of lamivudine-resistant HBV.

Combination Therapy

Recent updates in the guidelines recommend that since emtricitabine, lamivudine, TDF, and TAF are active against both viruses, patients with coinfection should start ART with a fixed-dose combination of TDF/emtricitabine or TAF/emtricitabine or the individual drug combination TDF plus lamivudine [53]. Most experts recommend the use of combination HBV therapy in patients on ART, particularly with lamivudine given the high rates of resistance.

• When should HBV treatment be started in patients with coinfection?

An ART regimen containing TDF (creatinine clearance > 50 mL/min) or TAF (creatinine clearance > 30 mL/min) with lamivudine or emtricitabine should be used in all HIV/HBV patients as soon as the infection is diagnosed. If TDF or TAF cannot be used, the alternate recommended regimen for HBV is entecavir plus a fully suppressive ART. In those with decreased renal function, entecavir should be adjusted to renal function [19].

Although control of viremia is feasible, clearance of infection as marked by loss of HBsAg and development of anti-HBs is unlikely to occur in the majority of patients. Therefore, the goals of treatment focus on prevention of chronic liver disease complications by suppressing viral replication, which can halt disease progression. A suggested algorithm for the management of coinfected patients is provided (Figure).

• What is the duration of therapy for hepatitis B?

Most patients with HIV/HBV coinfection will require lifelong treatment. All patients on HBV therapy as a part of ART should continue HBV therapy, regardless of seroconversion status. Also, patients should be educated and advised against self-discontinuation as it may trigger hepatitis exacerbations and/or hepatic failure.

Case Patient 3

Initial Presentation and History

Two months after starting treatment for HIV and chronic HBV infection, a 46-year-old Hispanic woman presents to clinic with jaundice and right upper quadrant (RUQ) pain. The patient was recently diagnosed with HIV infection and was naïve to treatment with ART. Her CD4 cell count was 50 cells/µL, and her HIV viral load was 743,000 copies/mL, with no baseline mutations on HIV genotype. The patient was also diagnosed with chronic HBV infection with positive HBsAg and HBeAg and negative HBc IgM serologies, as well as an HBV DNA level of 87 million IU/mL. Routine blood work revealed normal renal function and serum transaminases. The decision was made to start the patient on darunavir/ritonavir and TDF/emtricitabine. The patient was also started on sulfamethoxazole/trimethoprim and azithromycin for opportunistic infection prophylaxis.

Physical Examination and Laboratory Testing

Examination is remarkable for mild tenderness in the RUQ and icteric sclera. Laboratory testing demonstrates the following: AST, 1523 U/L; ALT, 795 U/L; albumin, 2.8 mg/dL; and total bilirubin, 3.5 mg/dL. Her CD4 count has increased to 565 cells/µL, and her HIV viral load is 4320 copies/mL. Results of repeat hepatitis serologies are as follows: HBsAg positive, anti-HBc IgM positive, and an HBV DNA level of 4.2 million IU/mL. Testing for hepatitis A, C, and D is negative, and RUQ sonogram reveals no gallstones.

• What monitoring should be done for coinfected patients on HBV therapy?

Monitoring

Providers should routinely monitor patients’ response to HIV/HBV therapy. Initially, all coinfected patients should have liver function tests and HBV DNA levels checked every 12 weeks on therapy. Frequent monitoring allows early detection of HBV drug resistance as well as drug-related hepatotoxicity. In HBeAg-positive coinfected patients who achieve HBV DNA suppression, HBeAg and anti-HBe testing should be performed every 6 to 12 months to assess for seroconversion. In HBeAg-negative patients, only HBV DNA and liver function tests are needed. HBV virologic failure is defined as a greater than 1-log10 rise in HBV DNA levels or development of viremia in a patient with a previously suppressed DNA level on therapy.

Typically, virologic failure results from either the development of drug resistance or abrupt withdrawal of active HBV therapy due to patient nonadherence or changes to the ART regimen. Virologic failure can result in a rise in serum aminotransferases as well as decompensation in patients with significant underlying liver disease. Due to this risk, providers must counsel patients about the importance of adherence to therapy and should continue medications active against HBV when making a change in ART regimens, unless HBV drug resistance dictates a change in HBV therapy.

• What is the likely cause of this patient’s hepatitis “flare”?

Several studies indicate that patients with HIV/HBV coinfection are at increased risk of drug-related hepatotoxicity and grade 4 liver enzyme elevations [54,55].The first 3 months after initiation of ART is a particularly vulnerable time for liver injury. The differential diagnosis for an acute hepatitis “flare” following the initiation of ART is broad and includes the following: development of HBV drug resistance [16]; withdrawal of HBV-active medications due to nonadherence [54]; ART-related hepatotoxicity; superimposed infection with HAV, HCV, or HDV; other opportunistic infections including cytomegalovirus and mycobacterium avium complex; or IRIS, resulting in an exaggerated cytotoxic response by the recovering immune system [56,57]. Complete evaluation is critical to distinguish between the possible causes.

In this case, several clues point toward HBV-related IRIS as the most likely cause for the hepatitis “flare.” A low pretreatment CD4 cell count with a rapid rise after initiation of ART is associated with a higher rate of IRIS [57]. Serologic testing and imaging excluded superinfection with another hepatotropic virus or biliary tract disease. Appropriate declines in HIV viral load and HBV DNA levels imply patient adherence to therapy and argue against the development of HBV drug resistance. Finally, the emergence of anti-HBc IgM positivity signals HBV reactivation, which is commonly seen in patients with HBV-related IRIS [57]. The preferred treatment for HBV-related IRIS involves continuation of therapy, frequently leading to normalization of aminotransferases and subsequent HBeAg seroconversion. Because IRIS usually manifests within the first 6 to 12 weeks after starting ART, liver enzymes should be monitored closely during this period.

• What health maintenance should be done for coinfected patients?

All patients with HIV/HBV coinfection should be monitored for evidence of portal hypertension or cirrhosis and, if these conditions exist, should undergo endoscopic screening for esophageal varices as well as evaluation of ascites and encephalopathy. Patients with HBV are at increased risk for the development of HCC even in the absence of cirrhosis. A recent study showed low rates of HCC screening in HIV/HBV patients by HIV providers [58]. Whether HIV coinfection potentiates HCC risk is uncertain, though coinfected patients present at younger ages and with more symptoms than HIV-negative comparators [59]. Other risk factors for HCC include HCV infection, alcohol abuse, diabetes, obesity, exposure to environmental toxins, and cirrhosis of any etiology (most commonly non-alcoholic fatty liver disease, primary sclerosing cholangitis, primary biliary cirrhosis and hemochromatosis) [60].

The American Association of Liver Diseases (AASLD) guidelines recommend hepatic ultrasound screening every 6 months in all patients with cirrhosis or chronic HBV who are at increased risk (Asian men over the age of 40 years, Asian women over the age of 50 years, African or North American blacks, and patients with family history of HCC) [61]. They should also be referred for an esophagogastroduodenoscopy to evaluate for esophageal varices. In addition, all HIV/HBV coinfected patients with decompensated liver disease should be evaluated for transplantation. HIV infection is not a contraindication for liver transplant with the use of ART. However, since transplantation does not cure HBV infection, post-transplant HBV immune globulin and HBV treatment are required. Contemporary data suggest comparable survival rates after transplant in coinfected patients compared to HBV-monoinfected patients [51].

Summary

Routine screening with HBsAg, anti-HBs, and anti-HBc serologies is recommended for all HIV-positive individuals. Patients without evidence of prior exposure or vaccination and those with isolated anti-HBc should be offered vaccination. HIV-positive adults should receive three or four 40 µg/mL doses of single agent vaccine depending on the recombinant vaccine type available. Anti-HBsAg titers should be checked 1 month after completion of the immunization series. If quantitative anti-HBsAg levels are < 10 IU/mL, patients should receive a second vaccine cycle.

Patients who test positive for HBsAg should be tested for HBeAg, anti-HBe, and HBV DNA levels and have AST and ALT levels checked as well. All patients with HIV/HBV coinfection should start treatment as soon as HIV infection is diagnosed. ART needs to include 2 drugs against HBV, and therefore a fixed-dose combination of TDF/emtricitabine or TAF/emtricitabine or the individual combination of TDF plus lamivudine should be used.

Coinfected patients on treatment should have liver function tests as well as HBV DNA every 12 weeks. In HBeAg-positive coinfected individuals who achieve HBV DNA suppression, HBeAg and anti-HBe testing should be performed every 6 to 12 months to assess for seroconversion. HBV virologic failure is defined as a greater than 1-log10 rise in HBV DNA levels or development of viremia in a patient with a previously suppressed DNA level on therapy. Those with virologic failure should be tested for HBV resistance thorough HBV genotype. Coinfected patients with cirrhosis should receive ultrasound screening every 6 months for evidence of HCC and esophagogastroduodenoscopy to evaluate for esophageal varices.

From UT Southwestern Medical Center, Dallas, TX.

Abstract

• Objective: To review the literature on and provide evidence-based recommendations for management of HIV/ hepatitis B (HBV) coinfection.
• Methods: Review of the literature for clinical trials, guidelines, and cohort studies on HIV/HBV disease management.
• Results: HIV patients should be evaluated for viral hepatitis. Those who do not have evidence of immunity should be vaccinated and monitored for response. Those who have HIV/HBV should have additional serologies checked to evaluate for hepatitis B e antigen status and level of viremia. All HIV/HBV coinfected patients should be started on antiretroviral therapy with tenofovir-based regimens. Those with HIV/HBV and cirrhosis should be screened for hepatocellular cancer every 6 months.
• Conclusion: HIV patients should be vaccinated against hepatitis B; those with coinfection should be treated for both viruses. It is important to monitor for treatment response to both HIV and HBV and liver disease complications.

Key words: incentives; reinforcement; substance abuse treatment; dissemination; implementation.

Morbidity and mortality for HIV-infected patients remain high compared to uninfected patients despite effective virologic suppression. Major contributors to illness and death among these patients include cardiovascular disease, non–AIDS-defining malignancies, and chronic liver disease, specifically viral hepatitis [1]. Hepatitis B virus (HBV) infection is one of the main causes of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) globally. Because HIV and HBV can both be acquired through injection drug use and sexual transmission, coinfection occurs frequently. The Joint United Nations Program on HIV/AIDS estimates that 10% of the 33 million HIV-positive patients worldwide have simultaneous chronic HBV infection [2].

HIV/HBV coinfection significantly impacts the natural history, progression, and mortality related to both viruses. HIV infection accelerates HBV-related liver impairment, leading to earlier cirrhosis, end-stage liver disease, and HCC. Conversely, chronic HBV does not have a considerable influence in the progression of HIV; however, antiretroviral treatment (ART) toxicities and/or HBV flares due to immune reconstitution inflammatory syndrome (IRIS) or HBV itself can lead to increased liver-related complications [3,4].

Case Patient 1

Initial Presentation and History

An asymptomatic 38-year-old man diagnosed with HIV infection 1 month ago presents for his initial visit to establish HIV care. The patient is a man who has sex with men (MSM) and is currently sexually active with multiple partners. He reports inconsistent use of condoms. One month ago he under­went routine screening and was found to be HIV-positive. At the time of diagnosis, the patient’s baseline CD4 cell count was 328 cells/µL and his viral load was 182,600 copies/mL. The patient wants to discuss the implications of his new diagnosis of HIV and recommendations for further testing and treatment. He is especially interested in HBV screening, since one of his recent partners was known to be positive. The patient has no relevant past medical history. He does not recall the details of his childhood vaccinations. He denies smoking and injection drug use but reports moderate alcohol consumption.

Physical Examination and Laboratory Testing

Physical examination is normal. Laboratory studies show normal complete blood count (CBC) and renal and liver function test results, and a baseline HIV genotype does not show resistance. Hepatitis A total antibody (anti-HAV) testing is positive, while tests for hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), and hepatitis C antibody (anti-HCV) are negative.

• Which screening tests for HBV should be performed in HIV-infected patients?

Routine screening of all HIV-infected patients for hepatitis A virus, HBV, and hepatitis C virus (HCV) is recommended [5]. Routine HBV screening involves obtaining serologies for HBsAg, anti-HBs, and anti-HBc. With these results, patients can be classified into categories of either active infection, immunity, or no evidence of prior exposure (Table 1).

• How effective is HBV vaccination in the HIV population?

Vaccination

Available HBV vaccines in the United States include 2 single-agent vaccines (Recombivax HB [Merck, Whitehouse Station, NJ] and Engerix-B [GlaxoSmithKline, Research Triangle Park, NC]) as well as a combination HAV/HBV vaccine (Twinrix [GlaxoSmithKline]). For adults (age ≥ 20 years) with an immunocompromising condition such as HIV infection, current Centers for Disease Control and Prevention guidelines recommend three 40 µg/mL doses of single-agent vaccine administered at 0, 1, and 6 months (Recombivax HB), or four 40 µg/mL doses of single-agent vaccine (2 doses of 20 µg/mL administered simultaneously) at 0, 1, 2, and 6 months (Engerix-B) [7].

The immunogenicity to HBV vaccination in HIV-positive patients is decreased, reflected by lower anti­body titers, waning immunity, and seroconversion rates of 18% to 65% [8–11]. Factors associated with poor response include low CD4 cell counts, detectable HIV RNA, coinfection with HCV, and the general health status of the patient [8]. Ideally, HBV vaccination should occur prior to decline in CD4 cell count below 350 cells/µL. However, guidelines do not recommend deferring vaccination since some patients with advanced HIV disease will seroconvert [6].

Anti-HBs titers should be checked 1 month after completion of the vaccine series to confirm protective antibody titers. For patients with quantitative anti-HBs levels < 10 IU/mL, a second vaccine cycle is recommended. Some specialists may defer revaccination until a sustained increase in CD4 count is achieved on ART.

Two randomized controlled trials have demonstrated that 4 doses of double-dose (40 µg/mL) vaccine generate higher anti-HBs levels than 3 doses of standard-dose (20 µg/mL) vaccine in HIV-infected adults [12,13]. Another study showed that HIV patients with CD4 counts > 350 cells/µL had better responses when immunized with double- dose vaccines on the usual 3-dose series [14]. Currently, the CDC recommends giving a double dose for either a 3-dose schedule or a 4-dose schedule. However, it remains unclear what dosing schedule to use if a patient fails to respond. Likely waiting until the CD4 cell count has increased and HIV viral load is suppressed will be important to seeing a response.

• What approach for HBV prevention should be taken in this patient?

The patient’s serologies confirm no prior exposure to HBV, and he should be offered HBV vaccination. His CD4 cell count is below 350/µL and he has ongoing HIV viremia, which increases his risk for an inadequate response. However, vaccination should not be delayed, particularly given his high risk of sexual transmission. The patient should be counseled regarding all high-risk behaviors. As discussed above, 3 or 4 doses of the higher dose vaccine (40 µg/mL) should be administered depending on what type of recombinant vaccine is available. An anti-HBs level should be checked 1 month after completion. A full repeat vaccine series using the 40 µg/mL dose should be considered for nonresponders who initially received a standard vaccine series. Experts also recommend checking annual anti-HBs levels to monitor for waning immunity, with a booster dose given if the anti-HBs level drops below the protective range.

• What vaccination strategy should be used in patients with isolated positive anti-HBc?

The clinical implications of an isolated positive anti-HBc for vaccination are still uncertain. This serologic pattern may represent a false-positive test, remote HBV infection with loss of anti-HBs, or occult HBV infection with undetectable HBsAg. The latter scenario appears more commonly in HIV-infected patients, particularly with concomitant HCV infection [15].

A recent study suggested that patients with an isolated positive anti-HBc with a negative anamnestic antibody response (anti-HBs titer of < 10 IU/mL 4 weeks after a single 20 µg dose of recombinant HBV vaccine) should be further vaccinated with the double-dose for a 3-dose schedule [6]. Additionally, another study followed HIV/HCV coinfected patients for 9.5 years and found that an isolated positive anti-HBc was not associated with accelerated liver disease progression [16].

Treatment of HIV-1 Infection

Current HIV guidelines recommend initiation of ART for all HIV-infected patients regardless of their CD4 count [17]. ART for a treatment-naïve patient usually consists of 2 nucleotide/nucleoside reverse-transcriptase inhibitors (NRTIs; the “backbone”) combined with a third agent (the “anchor”), which can be a nonnucleoside reverse-transcriptase inhibitor (NNRTI), a protease inhibitor (PI) boosted with a boosting agent, or an integrase strand-transfer inhibitor (INSTI) [18,19].

There are numerous studies indicating that incident HBV risk can be reduced by placing those at risk for HBV acquisition on ART containing a combination of tenofovir disoproxil fumarate (TDF), lamivudine, or emtricitabine [20,21]. Another study in MSM found those on ART with HIV viral load < 400 copies/mL were protected from developing HBV compared to those not on ART [22]. Given this patient’s higher risk for HBV acquisition, placing him on emtricitabine/TDF backbone as part of ART could be protective against incident HBV [23].

Case Patient 2

Initial Presentation and History

A 32-year-old man diagnosed with HIV infection 8 years ago now on ART presents for follow-up. The patient is an MSM with a history of inconsistent condom use. At the time of HIV diagnosis 8 years ago, the patient had a CD4 cell count of 250 cells/µL and an HIV viral load of 648,000 copies/mL. The patient was initiated on lamivudine/zidovudine and lopinavir/ritonavir, and he achieved complete virologic suppression at 20 weeks, with a CD4 cell count of 455 cells/µL at 1 year. The patient has remained on this regimen without major side effects; however, he reports frequent missed doses over the last 2 years due to “pill fatigue.” Previous testing for HBV and HCV at the time of his initial HIV diagnosis was negative, but he failed to complete the HBV vaccine series. He denies alcohol or injection drug use.

Physical Examination and Laboratory Testing

Physical examination is normal. Laboratory studies reveal normal electrolytes and renal function, hemoglobin of 11 g/dL, and platelet count of 235,000/µL. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels are 34 U/L and 44 U/L, respectively, with an INR of 1.1 and albumin level of 3.4 g/dL. CD4 cell count is 320 cells/µL with an HIV viral load of 24,500 copies/mL. Viral hepatitis serologies show anti-HAV positive, anti-HCV negative, HBsAg positive, anti-HBc IgG positive, hepatitis Be antigen (HBeAg) negative, and hepatitis B e antibody (anti-HBe) positive. HBV DNA viral load is 685,000 IU/mL.

• What is the natural history of HIV/HBV coinfection?

Chronic HBV infection affects about 10% of HIV-infected patients globally. Epidemiologic studies indicate that HIV-infected patients have higher rates of reactivation and progression to chronic HBV infection and chronic liver disease than HIV-negative patients [24–26]. Coinfected patients demonstrate higher serum HBV DNA levels, which lead to more rapid progression of hepatic fibrosis and may increase the risk of cirrhosis and HCC [24,27,28]. HIV infection, however, can mediate the necroinflammatory response through blunting of the immune response that drives pathogenesis in HBV infection. Aminotransferase levels may be only slightly elevated or even normal, particularly in the severely immune suppressed. However, elevation in liver enzymes (hepatitis flare) can occur if a patient stops ART, or if HBV resistance develops. Patients being treated for HIV/HBV coinfection should be counseled that stopping HIV treatment puts them at risk of developing a hepatitis flare.

Large cohort studies of HIV/HBV coinfected patients indicate increased risk of liver-related mortality, most pronounced with lower CD4 cell counts [1,28,29]. Introduction of ART appears to increase rather than attenuate this liver-related mortality, possibly by decreasing AIDS-related mortality and allowing more time for liver disease progression. Finally, a recent meta-analysis including 12,382 patients demonstrated a significant effect of HIV/HBV coinfection on all-cause mortality, with a pooled effect estimate of 1.36 [30].

• What diagnostic testing should be done in coinfected patients?

Diagnostic Testing and Evaluation

Persistence of HBsAg for more than 6 months is diagnostic of chronic HBV infection and warrants further serologic evaluation. Patients with chronic HBV infection should be tested for HBeAg, anti-HBe, and HBV DNA levels and have AST and ALT levels measured. Elevation of AST and ALT can be seen with untreated HBV. For those on treatment, a hepatitis flare could be caused by abrupt discontinuation of HBV treatment, development of HBV resistance, or superinfection with another viral pathogen.

HBeAg is a marker of active viral replication and is associated with higher levels of HBV DNA and active liver disease. Seroconversion, or loss of HBeAg and development of anti-HBe, heralds a favorable treatment response for those who were initially HBeAg-positive. However, some HBV variants have precore or core promoter mutations that lead to higher levels of HBV DNA in the absence of HBeAg. This highlights the importance of monitoring HBV DNA levels in all patients with chronic HBV infection. Favorable response to therapy in HBeAg-negative patients is marked by normalization of aminotransferases and HBV DNA suppression.Hepatitis D virus (HDV) is a defective virus particle that can only replicate in the presence of HBV. Coinfected patients should be tested for anti-HDV if they are injection drug users or are from a high-prevalence region such as the Mediterranean and Amazon basins. Newly acquired HDV infection should also be considered in the context of hepatitis flares.

Although these routine diagnostic tests are essential for management, studies show low adherence rates to HBV testing guidelines by HIV providers [31,32].

• What is the role of HBV genotype and resistance testing?

HBV can be classified into 10 different genotypes, A through J, based on genomic sequence variations. Each genotype has a distinct ethnic and geographic distribution, with genotypes A and D predominating in North America. HBV genotyping appears to have important prognostic as well as treatment implications [19]. However, data are still preliminary and the guidelines do not recommend routine genotype testing.

Resistance testing in HBV allows for detection of mutations that decrease effectiveness of antivirals. Exposure to lamivudine can lead to mutations in the YMDD region of the HBV DNA polymerase, resulting in drug resistance. Resistance to lamivudine develops at a rate of approximately 25% after 1 year of drug exposure in HIV/HBV coinfection [33]. On the other hand, studies have shown that entecavir is active against HIV and, most importantly, selects for the M184V mutation in HIV. M184V is associated with lamivudine resistance for HIV treatment, thus limiting treatment options [34,35]. After these findings, the FDA advised against monotherapy with entecavir in patients with HIV/HBV coinfection. The case patient was on lamivudine during the time of HBV acquisition, and therefore YMDD mutation must be taken into consideration for therapy purposes. He should be switched to a regimen that suppresses both viruses. The development of drug resistance should be assessed in all patients with persistent or breakthrough HBV viremia on ART, particularly the nucleoside analogues. HIV providers treating HIV/HBV coinfection should regularly monitor both HIV and HBV viral load to assess for therapeutic efficacy.

• What is the role of liver biopsy in this patient?

Liver biopsy should be considered in all coinfected patients as it remains the gold standard for determining the activity and severity of chronic hepatitis B. However, because it carries inherent risks and is not required prior to treatment in all patients, the decision should be individualized. Liver biopsy can be useful to assess baseline liver histology and may be warranted to rule out significant coexisting genetic or metabolic liver disease. Currently, noninvasive methods to assess liver fibrosis either using elastography or various combinations of serum biomarkers are being evaluated [36] and may be considered in lieu of a liver biopsy [37]. One study compared the accuracy of elastography with liver biopsy in HIV/HBV coinfected patients and demonstrated that the former was proficient in discriminating between absence or mild fibrosis and moderate to severe fibrosis [38]. In general, this test has high accuracy in detecting minimal fibrosis from advanced fibrosis or cirrhosis. For the group in the middle, further investigation with additional methods must be considered [37]. Finally, a recent retrospective study involving 70 HIV/HBV coinfected individuals showed fibrosis regression suggesting beneficial effects of long-term ART on liver stiffness, [39] but further studies are needed to confirm these findings.

Case 2 Continued

The patient has now been diagnosed with chronic HBV infection. His diagnostic testing is negative for HBeAg and reveals modest HBV viremia with abnormal aminotransferases less than 2 times the upper limit of normal. Drug resistance testing reveals a mutation in the YMDD region indicative of HBV lamivudine resistance. HIV genotype demonstrates a wild-type virus without resistance. The patient asks what treatment options exist.

• What medications are currently available to treat hepatitis B?

Treatment

All patients with HIV/HBV coinfection should receive treatment to suppress both viruses, and ART needs to include 2 drugs active against HBV, ideally emtricitabine and TDF. This approach prevents drug resistance, slows progression of HBV infection, and reduces the incidence of IRIS [5]. TDF has been associated with decreased renal function and bone mineral density. Recently, tenofovir alafenamide fumarate (TAF) was approved for the treatment of HIV and HBV. A dose of 10 mg daily is given when coadministered with ritonavir, cobicistat, or protease inhibitors, but a dose of 25 mg should be given when administered with NNRTIs or integrase inhibitors. Compared to TDF, TAF shows less accumulation of tenofovir in kidneys and bones and consequently has reduced renal and bone mineral density effects [40]. All patients should be on a TDF- or TAF-based HIV regimen if they have chronic HBV.

Currently, the following antiviral drugs are FDA-approved for the treatment of HBV infection: interferon alfa-2b, pegylated interferon (peginterferon) alfa-2a, lamivudine and emtricitabine, entecavir, adefovir, TDF, TAF, and telbivudine. Telbivudine and adefovir are no longer recommended due to their association with higher incidence of toxicity and higher rates of HBV treatment failure. A summary of available HBV treatment options is outlined in Table 2.

Interferon

Standard interferon alfa-2b blocks HBV replication through interaction with viral proteins and stimulation of host cellular immunity. Peginterferon alfa-2a has proven efficacy in HBV-monoinfected patients, but efficacy data in HIV/HBV coinfected patients is lacking [41,42]. Studies in hepatitis C treatment demonstrate the safety of peginterferon alfa-2a use in HIV-positive patients and indicate that HIV viral suppression occurs with peginterferon without evidence of selection of resistance mutations that affect future ART options [43]. For HIV/HBV coinfected patients not on ART who will receive only therapy for HBV (which is infrequent since all HIV patients should be on ART), pegylated interferon-alfa-2a alone for 48 weeks is the only option that will not cause ART-associated HIV drug resistance [5]. Interferon therapy is contraindicated in patients with decompensated cirrhosis and should be used with caution in patients with active depression, uncontrolled diabetes, and cardiac and pulmonary disease.

Lamivudine and Emtricitabine

Lamivudine is a nucleoside analogue with efficacy against both HIV and HBV. Clinical trials in HIV/HBV-infected patients have shown up to 87% of patients achieve undetectable HBV DNA levels and about 25% achieve HBeAg seroconversion after 1 to 2 years of therapy [44,45]. However, the major issue limiting use of lamivudine is its low genetic barrier to resistance. Mutation of the YMDD motif of the HBV DNA polymerase confers HBV resistance. HIV/HBV coinfected patients develop resistance at rates of up to 94% after 4 years of therapy [33], heralded by rebounds in HBV DNA levels and often hepatitis flares or precipitation of hepatic failure [16]. Because of resistance, lamivudine monotherapy should be avoided; even in patients on ART, abrupt withdrawal of lamivudine or the development of HBV resistance should be closely monitored.

Emtricitabine is another nucleoside analogue with properties and efficacy similar to lamivudine. It is frequently used as a combination pill with TDF (Truvada) in coinfected patients. The same concerns regarding monotherapy and the emergence of resistance that exist for lamivudine apply to emtricitabine.

Tenofovir

TDF, a nucleotide analogue, is one of the preferred first-line agents for HIV treatment and has proven efficacy against both wild-type and lamivudine-resistant HBV. Since it was first used for HIV, TDF has been more extensively studied in coinfected patients compared to most other agents. In a meta-analysis of patients with HIV/HBV coinfection, TDF suppressed HBV viral load to undetectable titers in approximately 90% of patients [46]. Tenofovir is available in 2 preparations: TDF and TAF. TDF has been reported to cause renal impairment as well as bone loss. TAF has shown less renal toxicity and less bone damage [40,47]. In 2016, TAF became available as part as 4 regimens: stand-alone TAF, elvitegravir-cobicistat-emtricitabine-TAF, rilpivirine-emtricitabine-TAF, and TAF-emtricitabine.

TDF and TAF both suppress HIV. Two large randomized trials of HBV monoinfection demonstrate that TAF is noninferior to TDF for the treatment of naïve and treatment-experienced patients [48,49].

Entecavir

Entecavir, a guanosine analogue, is a potent HBV DNA polymerase inhibitor that results in greater virologic suppression compared to lamivudine and retains activity against lamivudine-resistant HBV [50]. Importantly, entecavir shares some cross-resistance with lamivudine, so an entecavir dose of 1 mg daily is recommended in lamivudine-experienced patients compared to 0.5 mg daily in lamivudine-naïve patients. Entecavir requires dose reduction for patients with creatinine clearance less than 50 mL/min, although it is not associated with renal toxicity. A 1-log10 reduction in HIV RNA levels as well as emergence of M184V mutations on entecavir monotherapy has been reported [51,52]. M184V confers HIV resistance to lamivudine and emtricitabine. Therefore, entecavir should not be used as monotherapy in HIV-coinfected patients and/or patients with evidence of lamivudine-resistant HBV.

Combination Therapy

Recent updates in the guidelines recommend that since emtricitabine, lamivudine, TDF, and TAF are active against both viruses, patients with coinfection should start ART with a fixed-dose combination of TDF/emtricitabine or TAF/emtricitabine or the individual drug combination TDF plus lamivudine [53]. Most experts recommend the use of combination HBV therapy in patients on ART, particularly with lamivudine given the high rates of resistance.

• When should HBV treatment be started in patients with coinfection?

An ART regimen containing TDF (creatinine clearance > 50 mL/min) or TAF (creatinine clearance > 30 mL/min) with lamivudine or emtricitabine should be used in all HIV/HBV patients as soon as the infection is diagnosed. If TDF or TAF cannot be used, the alternate recommended regimen for HBV is entecavir plus a fully suppressive ART. In those with decreased renal function, entecavir should be adjusted to renal function [19].

Although control of viremia is feasible, clearance of infection as marked by loss of HBsAg and development of anti-HBs is unlikely to occur in the majority of patients. Therefore, the goals of treatment focus on prevention of chronic liver disease complications by suppressing viral replication, which can halt disease progression. A suggested algorithm for the management of coinfected patients is provided (Figure).

• What is the duration of therapy for hepatitis B?

Most patients with HIV/HBV coinfection will require lifelong treatment. All patients on HBV therapy as a part of ART should continue HBV therapy, regardless of seroconversion status. Also, patients should be educated and advised against self-discontinuation as it may trigger hepatitis exacerbations and/or hepatic failure.

Case Patient 3

Initial Presentation and History

Two months after starting treatment for HIV and chronic HBV infection, a 46-year-old Hispanic woman presents to clinic with jaundice and right upper quadrant (RUQ) pain. The patient was recently diagnosed with HIV infection and was naïve to treatment with ART. Her CD4 cell count was 50 cells/µL, and her HIV viral load was 743,000 copies/mL, with no baseline mutations on HIV genotype. The patient was also diagnosed with chronic HBV infection with positive HBsAg and HBeAg and negative HBc IgM serologies, as well as an HBV DNA level of 87 million IU/mL. Routine blood work revealed normal renal function and serum transaminases. The decision was made to start the patient on darunavir/ritonavir and TDF/emtricitabine. The patient was also started on sulfamethoxazole/trimethoprim and azithromycin for opportunistic infection prophylaxis.

Physical Examination and Laboratory Testing

Examination is remarkable for mild tenderness in the RUQ and icteric sclera. Laboratory testing demonstrates the following: AST, 1523 U/L; ALT, 795 U/L; albumin, 2.8 mg/dL; and total bilirubin, 3.5 mg/dL. Her CD4 count has increased to 565 cells/µL, and her HIV viral load is 4320 copies/mL. Results of repeat hepatitis serologies are as follows: HBsAg positive, anti-HBc IgM positive, and an HBV DNA level of 4.2 million IU/mL. Testing for hepatitis A, C, and D is negative, and RUQ sonogram reveals no gallstones.

• What monitoring should be done for coinfected patients on HBV therapy?

Monitoring

Providers should routinely monitor patients’ response to HIV/HBV therapy. Initially, all coinfected patients should have liver function tests and HBV DNA levels checked every 12 weeks on therapy. Frequent monitoring allows early detection of HBV drug resistance as well as drug-related hepatotoxicity. In HBeAg-positive coinfected patients who achieve HBV DNA suppression, HBeAg and anti-HBe testing should be performed every 6 to 12 months to assess for seroconversion. In HBeAg-negative patients, only HBV DNA and liver function tests are needed. HBV virologic failure is defined as a greater than 1-log10 rise in HBV DNA levels or development of viremia in a patient with a previously suppressed DNA level on therapy.

Typically, virologic failure results from either the development of drug resistance or abrupt withdrawal of active HBV therapy due to patient nonadherence or changes to the ART regimen. Virologic failure can result in a rise in serum aminotransferases as well as decompensation in patients with significant underlying liver disease. Due to this risk, providers must counsel patients about the importance of adherence to therapy and should continue medications active against HBV when making a change in ART regimens, unless HBV drug resistance dictates a change in HBV therapy.

• What is the likely cause of this patient’s hepatitis “flare”?

Several studies indicate that patients with HIV/HBV coinfection are at increased risk of drug-related hepatotoxicity and grade 4 liver enzyme elevations [54,55].The first 3 months after initiation of ART is a particularly vulnerable time for liver injury. The differential diagnosis for an acute hepatitis “flare” following the initiation of ART is broad and includes the following: development of HBV drug resistance [16]; withdrawal of HBV-active medications due to nonadherence [54]; ART-related hepatotoxicity; superimposed infection with HAV, HCV, or HDV; other opportunistic infections including cytomegalovirus and mycobacterium avium complex; or IRIS, resulting in an exaggerated cytotoxic response by the recovering immune system [56,57]. Complete evaluation is critical to distinguish between the possible causes.

In this case, several clues point toward HBV-related IRIS as the most likely cause for the hepatitis “flare.” A low pretreatment CD4 cell count with a rapid rise after initiation of ART is associated with a higher rate of IRIS [57]. Serologic testing and imaging excluded superinfection with another hepatotropic virus or biliary tract disease. Appropriate declines in HIV viral load and HBV DNA levels imply patient adherence to therapy and argue against the development of HBV drug resistance. Finally, the emergence of anti-HBc IgM positivity signals HBV reactivation, which is commonly seen in patients with HBV-related IRIS [57]. The preferred treatment for HBV-related IRIS involves continuation of therapy, frequently leading to normalization of aminotransferases and subsequent HBeAg seroconversion. Because IRIS usually manifests within the first 6 to 12 weeks after starting ART, liver enzymes should be monitored closely during this period.

• What health maintenance should be done for coinfected patients?

All patients with HIV/HBV coinfection should be monitored for evidence of portal hypertension or cirrhosis and, if these conditions exist, should undergo endoscopic screening for esophageal varices as well as evaluation of ascites and encephalopathy. Patients with HBV are at increased risk for the development of HCC even in the absence of cirrhosis. A recent study showed low rates of HCC screening in HIV/HBV patients by HIV providers [58]. Whether HIV coinfection potentiates HCC risk is uncertain, though coinfected patients present at younger ages and with more symptoms than HIV-negative comparators [59]. Other risk factors for HCC include HCV infection, alcohol abuse, diabetes, obesity, exposure to environmental toxins, and cirrhosis of any etiology (most commonly non-alcoholic fatty liver disease, primary sclerosing cholangitis, primary biliary cirrhosis and hemochromatosis) [60].

The American Association of Liver Diseases (AASLD) guidelines recommend hepatic ultrasound screening every 6 months in all patients with cirrhosis or chronic HBV who are at increased risk (Asian men over the age of 40 years, Asian women over the age of 50 years, African or North American blacks, and patients with family history of HCC) [61]. They should also be referred for an esophagogastroduodenoscopy to evaluate for esophageal varices. In addition, all HIV/HBV coinfected patients with decompensated liver disease should be evaluated for transplantation. HIV infection is not a contraindication for liver transplant with the use of ART. However, since transplantation does not cure HBV infection, post-transplant HBV immune globulin and HBV treatment are required. Contemporary data suggest comparable survival rates after transplant in coinfected patients compared to HBV-monoinfected patients [51].

Summary

Routine screening with HBsAg, anti-HBs, and anti-HBc serologies is recommended for all HIV-positive individuals. Patients without evidence of prior exposure or vaccination and those with isolated anti-HBc should be offered vaccination. HIV-positive adults should receive three or four 40 µg/mL doses of single agent vaccine depending on the recombinant vaccine type available. Anti-HBsAg titers should be checked 1 month after completion of the immunization series. If quantitative anti-HBsAg levels are < 10 IU/mL, patients should receive a second vaccine cycle.

Patients who test positive for HBsAg should be tested for HBeAg, anti-HBe, and HBV DNA levels and have AST and ALT levels checked as well. All patients with HIV/HBV coinfection should start treatment as soon as HIV infection is diagnosed. ART needs to include 2 drugs against HBV, and therefore a fixed-dose combination of TDF/emtricitabine or TAF/emtricitabine or the individual combination of TDF plus lamivudine should be used.

Coinfected patients on treatment should have liver function tests as well as HBV DNA every 12 weeks. In HBeAg-positive coinfected individuals who achieve HBV DNA suppression, HBeAg and anti-HBe testing should be performed every 6 to 12 months to assess for seroconversion. HBV virologic failure is defined as a greater than 1-log10 rise in HBV DNA levels or development of viremia in a patient with a previously suppressed DNA level on therapy. Those with virologic failure should be tested for HBV resistance thorough HBV genotype. Coinfected patients with cirrhosis should receive ultrasound screening every 6 months for evidence of HCC and esophagogastroduodenoscopy to evaluate for esophageal varices.

From UT Southwestern Medical Center, Dallas, TX.

Abstract

• Objective: To review the literature on and provide evidence-based recommendations for management of HIV/ hepatitis B (HBV) coinfection.
• Methods: Review of the literature for clinical trials, guidelines, and cohort studies on HIV/HBV disease management.
• Results: HIV patients should be evaluated for viral hepatitis. Those who do not have evidence of immunity should be vaccinated and monitored for response. Those who have HIV/HBV should have additional serologies checked to evaluate for hepatitis B e antigen status and level of viremia. All HIV/HBV coinfected patients should be started on antiretroviral therapy with tenofovir-based regimens. Those with HIV/HBV and cirrhosis should be screened for hepatocellular cancer every 6 months.
• Conclusion: HIV patients should be vaccinated against hepatitis B; those with coinfection should be treated for both viruses. It is important to monitor for treatment response to both HIV and HBV and liver disease complications.

Key words: incentives; reinforcement; substance abuse treatment; dissemination; implementation.

Morbidity and mortality for HIV-infected patients remain high compared to uninfected patients despite effective virologic suppression. Major contributors to illness and death among these patients include cardiovascular disease, non–AIDS-defining malignancies, and chronic liver disease, specifically viral hepatitis [1]. Hepatitis B virus (HBV) infection is one of the main causes of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) globally. Because HIV and HBV can both be acquired through injection drug use and sexual transmission, coinfection occurs frequently. The Joint United Nations Program on HIV/AIDS estimates that 10% of the 33 million HIV-positive patients worldwide have simultaneous chronic HBV infection [2].

HIV/HBV coinfection significantly impacts the natural history, progression, and mortality related to both viruses. HIV infection accelerates HBV-related liver impairment, leading to earlier cirrhosis, end-stage liver disease, and HCC. Conversely, chronic HBV does not have a considerable influence in the progression of HIV; however, antiretroviral treatment (ART) toxicities and/or HBV flares due to immune reconstitution inflammatory syndrome (IRIS) or HBV itself can lead to increased liver-related complications [3,4].

Case Patient 1

Initial Presentation and History

An asymptomatic 38-year-old man diagnosed with HIV infection 1 month ago presents for his initial visit to establish HIV care. The patient is a man who has sex with men (MSM) and is currently sexually active with multiple partners. He reports inconsistent use of condoms. One month ago he under­went routine screening and was found to be HIV-positive. At the time of diagnosis, the patient’s baseline CD4 cell count was 328 cells/µL and his viral load was 182,600 copies/mL. The patient wants to discuss the implications of his new diagnosis of HIV and recommendations for further testing and treatment. He is especially interested in HBV screening, since one of his recent partners was known to be positive. The patient has no relevant past medical history. He does not recall the details of his childhood vaccinations. He denies smoking and injection drug use but reports moderate alcohol consumption.

Physical Examination and Laboratory Testing

Physical examination is normal. Laboratory studies show normal complete blood count (CBC) and renal and liver function test results, and a baseline HIV genotype does not show resistance. Hepatitis A total antibody (anti-HAV) testing is positive, while tests for hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), and hepatitis C antibody (anti-HCV) are negative.

• Which screening tests for HBV should be performed in HIV-infected patients?

Routine screening of all HIV-infected patients for hepatitis A virus, HBV, and hepatitis C virus (HCV) is recommended [5]. Routine HBV screening involves obtaining serologies for HBsAg, anti-HBs, and anti-HBc. With these results, patients can be classified into categories of either active infection, immunity, or no evidence of prior exposure (Table 1).

• How effective is HBV vaccination in the HIV population?

Vaccination

Available HBV vaccines in the United States include 2 single-agent vaccines (Recombivax HB [Merck, Whitehouse Station, NJ] and Engerix-B [GlaxoSmithKline, Research Triangle Park, NC]) as well as a combination HAV/HBV vaccine (Twinrix [GlaxoSmithKline]). For adults (age ≥ 20 years) with an immunocompromising condition such as HIV infection, current Centers for Disease Control and Prevention guidelines recommend three 40 µg/mL doses of single-agent vaccine administered at 0, 1, and 6 months (Recombivax HB), or four 40 µg/mL doses of single-agent vaccine (2 doses of 20 µg/mL administered simultaneously) at 0, 1, 2, and 6 months (Engerix-B) [7].

The immunogenicity to HBV vaccination in HIV-positive patients is decreased, reflected by lower anti­body titers, waning immunity, and seroconversion rates of 18% to 65% [8–11]. Factors associated with poor response include low CD4 cell counts, detectable HIV RNA, coinfection with HCV, and the general health status of the patient [8]. Ideally, HBV vaccination should occur prior to decline in CD4 cell count below 350 cells/µL. However, guidelines do not recommend deferring vaccination since some patients with advanced HIV disease will seroconvert [6].

Anti-HBs titers should be checked 1 month after completion of the vaccine series to confirm protective antibody titers. For patients with quantitative anti-HBs levels < 10 IU/mL, a second vaccine cycle is recommended. Some specialists may defer revaccination until a sustained increase in CD4 count is achieved on ART.

Two randomized controlled trials have demonstrated that 4 doses of double-dose (40 µg/mL) vaccine generate higher anti-HBs levels than 3 doses of standard-dose (20 µg/mL) vaccine in HIV-infected adults [12,13]. Another study showed that HIV patients with CD4 counts > 350 cells/µL had better responses when immunized with double- dose vaccines on the usual 3-dose series [14]. Currently, the CDC recommends giving a double dose for either a 3-dose schedule or a 4-dose schedule. However, it remains unclear what dosing schedule to use if a patient fails to respond. Likely waiting until the CD4 cell count has increased and HIV viral load is suppressed will be important to seeing a response.

• What approach for HBV prevention should be taken in this patient?

The patient’s serologies confirm no prior exposure to HBV, and he should be offered HBV vaccination. His CD4 cell count is below 350/µL and he has ongoing HIV viremia, which increases his risk for an inadequate response. However, vaccination should not be delayed, particularly given his high risk of sexual transmission. The patient should be counseled regarding all high-risk behaviors. As discussed above, 3 or 4 doses of the higher dose vaccine (40 µg/mL) should be administered depending on what type of recombinant vaccine is available. An anti-HBs level should be checked 1 month after completion. A full repeat vaccine series using the 40 µg/mL dose should be considered for nonresponders who initially received a standard vaccine series. Experts also recommend checking annual anti-HBs levels to monitor for waning immunity, with a booster dose given if the anti-HBs level drops below the protective range.

• What vaccination strategy should be used in patients with isolated positive anti-HBc?

The clinical implications of an isolated positive anti-HBc for vaccination are still uncertain. This serologic pattern may represent a false-positive test, remote HBV infection with loss of anti-HBs, or occult HBV infection with undetectable HBsAg. The latter scenario appears more commonly in HIV-infected patients, particularly with concomitant HCV infection [15].

A recent study suggested that patients with an isolated positive anti-HBc with a negative anamnestic antibody response (anti-HBs titer of < 10 IU/mL 4 weeks after a single 20 µg dose of recombinant HBV vaccine) should be further vaccinated with the double-dose for a 3-dose schedule [6]. Additionally, another study followed HIV/HCV coinfected patients for 9.5 years and found that an isolated positive anti-HBc was not associated with accelerated liver disease progression [16].

Treatment of HIV-1 Infection

Current HIV guidelines recommend initiation of ART for all HIV-infected patients regardless of their CD4 count [17]. ART for a treatment-naïve patient usually consists of 2 nucleotide/nucleoside reverse-transcriptase inhibitors (NRTIs; the “backbone”) combined with a third agent (the “anchor”), which can be a nonnucleoside reverse-transcriptase inhibitor (NNRTI), a protease inhibitor (PI) boosted with a boosting agent, or an integrase strand-transfer inhibitor (INSTI) [18,19].

There are numerous studies indicating that incident HBV risk can be reduced by placing those at risk for HBV acquisition on ART containing a combination of tenofovir disoproxil fumarate (TDF), lamivudine, or emtricitabine [20,21]. Another study in MSM found those on ART with HIV viral load < 400 copies/mL were protected from developing HBV compared to those not on ART [22]. Given this patient’s higher risk for HBV acquisition, placing him on emtricitabine/TDF backbone as part of ART could be protective against incident HBV [23].

Case Patient 2

Initial Presentation and History

A 32-year-old man diagnosed with HIV infection 8 years ago now on ART presents for follow-up. The patient is an MSM with a history of inconsistent condom use. At the time of HIV diagnosis 8 years ago, the patient had a CD4 cell count of 250 cells/µL and an HIV viral load of 648,000 copies/mL. The patient was initiated on lamivudine/zidovudine and lopinavir/ritonavir, and he achieved complete virologic suppression at 20 weeks, with a CD4 cell count of 455 cells/µL at 1 year. The patient has remained on this regimen without major side effects; however, he reports frequent missed doses over the last 2 years due to “pill fatigue.” Previous testing for HBV and HCV at the time of his initial HIV diagnosis was negative, but he failed to complete the HBV vaccine series. He denies alcohol or injection drug use.

Physical Examination and Laboratory Testing

Physical examination is normal. Laboratory studies reveal normal electrolytes and renal function, hemoglobin of 11 g/dL, and platelet count of 235,000/µL. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels are 34 U/L and 44 U/L, respectively, with an INR of 1.1 and albumin level of 3.4 g/dL. CD4 cell count is 320 cells/µL with an HIV viral load of 24,500 copies/mL. Viral hepatitis serologies show anti-HAV positive, anti-HCV negative, HBsAg positive, anti-HBc IgG positive, hepatitis Be antigen (HBeAg) negative, and hepatitis B e antibody (anti-HBe) positive. HBV DNA viral load is 685,000 IU/mL.

• What is the natural history of HIV/HBV coinfection?

Chronic HBV infection affects about 10% of HIV-infected patients globally. Epidemiologic studies indicate that HIV-infected patients have higher rates of reactivation and progression to chronic HBV infection and chronic liver disease than HIV-negative patients [24–26]. Coinfected patients demonstrate higher serum HBV DNA levels, which lead to more rapid progression of hepatic fibrosis and may increase the risk of cirrhosis and HCC [24,27,28]. HIV infection, however, can mediate the necroinflammatory response through blunting of the immune response that drives pathogenesis in HBV infection. Aminotransferase levels may be only slightly elevated or even normal, particularly in the severely immune suppressed. However, elevation in liver enzymes (hepatitis flare) can occur if a patient stops ART, or if HBV resistance develops. Patients being treated for HIV/HBV coinfection should be counseled that stopping HIV treatment puts them at risk of developing a hepatitis flare.

Large cohort studies of HIV/HBV coinfected patients indicate increased risk of liver-related mortality, most pronounced with lower CD4 cell counts [1,28,29]. Introduction of ART appears to increase rather than attenuate this liver-related mortality, possibly by decreasing AIDS-related mortality and allowing more time for liver disease progression. Finally, a recent meta-analysis including 12,382 patients demonstrated a significant effect of HIV/HBV coinfection on all-cause mortality, with a pooled effect estimate of 1.36 [30].

• What diagnostic testing should be done in coinfected patients?

Diagnostic Testing and Evaluation

Persistence of HBsAg for more than 6 months is diagnostic of chronic HBV infection and warrants further serologic evaluation. Patients with chronic HBV infection should be tested for HBeAg, anti-HBe, and HBV DNA levels and have AST and ALT levels measured. Elevation of AST and ALT can be seen with untreated HBV. For those on treatment, a hepatitis flare could be caused by abrupt discontinuation of HBV treatment, development of HBV resistance, or superinfection with another viral pathogen.

HBeAg is a marker of active viral replication and is associated with higher levels of HBV DNA and active liver disease. Seroconversion, or loss of HBeAg and development of anti-HBe, heralds a favorable treatment response for those who were initially HBeAg-positive. However, some HBV variants have precore or core promoter mutations that lead to higher levels of HBV DNA in the absence of HBeAg. This highlights the importance of monitoring HBV DNA levels in all patients with chronic HBV infection. Favorable response to therapy in HBeAg-negative patients is marked by normalization of aminotransferases and HBV DNA suppression.Hepatitis D virus (HDV) is a defective virus particle that can only replicate in the presence of HBV. Coinfected patients should be tested for anti-HDV if they are injection drug users or are from a high-prevalence region such as the Mediterranean and Amazon basins. Newly acquired HDV infection should also be considered in the context of hepatitis flares.

Although these routine diagnostic tests are essential for management, studies show low adherence rates to HBV testing guidelines by HIV providers [31,32].

• What is the role of HBV genotype and resistance testing?

HBV can be classified into 10 different genotypes, A through J, based on genomic sequence variations. Each genotype has a distinct ethnic and geographic distribution, with genotypes A and D predominating in North America. HBV genotyping appears to have important prognostic as well as treatment implications [19]. However, data are still preliminary and the guidelines do not recommend routine genotype testing.

Resistance testing in HBV allows for detection of mutations that decrease effectiveness of antivirals. Exposure to lamivudine can lead to mutations in the YMDD region of the HBV DNA polymerase, resulting in drug resistance. Resistance to lamivudine develops at a rate of approximately 25% after 1 year of drug exposure in HIV/HBV coinfection [33]. On the other hand, studies have shown that entecavir is active against HIV and, most importantly, selects for the M184V mutation in HIV. M184V is associated with lamivudine resistance for HIV treatment, thus limiting treatment options [34,35]. After these findings, the FDA advised against monotherapy with entecavir in patients with HIV/HBV coinfection. The case patient was on lamivudine during the time of HBV acquisition, and therefore YMDD mutation must be taken into consideration for therapy purposes. He should be switched to a regimen that suppresses both viruses. The development of drug resistance should be assessed in all patients with persistent or breakthrough HBV viremia on ART, particularly the nucleoside analogues. HIV providers treating HIV/HBV coinfection should regularly monitor both HIV and HBV viral load to assess for therapeutic efficacy.

• What is the role of liver biopsy in this patient?

Liver biopsy should be considered in all coinfected patients as it remains the gold standard for determining the activity and severity of chronic hepatitis B. However, because it carries inherent risks and is not required prior to treatment in all patients, the decision should be individualized. Liver biopsy can be useful to assess baseline liver histology and may be warranted to rule out significant coexisting genetic or metabolic liver disease. Currently, noninvasive methods to assess liver fibrosis either using elastography or various combinations of serum biomarkers are being evaluated [36] and may be considered in lieu of a liver biopsy [37]. One study compared the accuracy of elastography with liver biopsy in HIV/HBV coinfected patients and demonstrated that the former was proficient in discriminating between absence or mild fibrosis and moderate to severe fibrosis [38]. In general, this test has high accuracy in detecting minimal fibrosis from advanced fibrosis or cirrhosis. For the group in the middle, further investigation with additional methods must be considered [37]. Finally, a recent retrospective study involving 70 HIV/HBV coinfected individuals showed fibrosis regression suggesting beneficial effects of long-term ART on liver stiffness, [39] but further studies are needed to confirm these findings.

Case 2 Continued

The patient has now been diagnosed with chronic HBV infection. His diagnostic testing is negative for HBeAg and reveals modest HBV viremia with abnormal aminotransferases less than 2 times the upper limit of normal. Drug resistance testing reveals a mutation in the YMDD region indicative of HBV lamivudine resistance. HIV genotype demonstrates a wild-type virus without resistance. The patient asks what treatment options exist.

• What medications are currently available to treat hepatitis B?

Treatment

All patients with HIV/HBV coinfection should receive treatment to suppress both viruses, and ART needs to include 2 drugs active against HBV, ideally emtricitabine and TDF. This approach prevents drug resistance, slows progression of HBV infection, and reduces the incidence of IRIS [5]. TDF has been associated with decreased renal function and bone mineral density. Recently, tenofovir alafenamide fumarate (TAF) was approved for the treatment of HIV and HBV. A dose of 10 mg daily is given when coadministered with ritonavir, cobicistat, or protease inhibitors, but a dose of 25 mg should be given when administered with NNRTIs or integrase inhibitors. Compared to TDF, TAF shows less accumulation of tenofovir in kidneys and bones and consequently has reduced renal and bone mineral density effects [40]. All patients should be on a TDF- or TAF-based HIV regimen if they have chronic HBV.

Currently, the following antiviral drugs are FDA-approved for the treatment of HBV infection: interferon alfa-2b, pegylated interferon (peginterferon) alfa-2a, lamivudine and emtricitabine, entecavir, adefovir, TDF, TAF, and telbivudine. Telbivudine and adefovir are no longer recommended due to their association with higher incidence of toxicity and higher rates of HBV treatment failure. A summary of available HBV treatment options is outlined in Table 2.

Interferon

Standard interferon alfa-2b blocks HBV replication through interaction with viral proteins and stimulation of host cellular immunity. Peginterferon alfa-2a has proven efficacy in HBV-monoinfected patients, but efficacy data in HIV/HBV coinfected patients is lacking [41,42]. Studies in hepatitis C treatment demonstrate the safety of peginterferon alfa-2a use in HIV-positive patients and indicate that HIV viral suppression occurs with peginterferon without evidence of selection of resistance mutations that affect future ART options [43]. For HIV/HBV coinfected patients not on ART who will receive only therapy for HBV (which is infrequent since all HIV patients should be on ART), pegylated interferon-alfa-2a alone for 48 weeks is the only option that will not cause ART-associated HIV drug resistance [5]. Interferon therapy is contraindicated in patients with decompensated cirrhosis and should be used with caution in patients with active depression, uncontrolled diabetes, and cardiac and pulmonary disease.

Lamivudine and Emtricitabine

Lamivudine is a nucleoside analogue with efficacy against both HIV and HBV. Clinical trials in HIV/HBV-infected patients have shown up to 87% of patients achieve undetectable HBV DNA levels and about 25% achieve HBeAg seroconversion after 1 to 2 years of therapy [44,45]. However, the major issue limiting use of lamivudine is its low genetic barrier to resistance. Mutation of the YMDD motif of the HBV DNA polymerase confers HBV resistance. HIV/HBV coinfected patients develop resistance at rates of up to 94% after 4 years of therapy [33], heralded by rebounds in HBV DNA levels and often hepatitis flares or precipitation of hepatic failure [16]. Because of resistance, lamivudine monotherapy should be avoided; even in patients on ART, abrupt withdrawal of lamivudine or the development of HBV resistance should be closely monitored.

Emtricitabine is another nucleoside analogue with properties and efficacy similar to lamivudine. It is frequently used as a combination pill with TDF (Truvada) in coinfected patients. The same concerns regarding monotherapy and the emergence of resistance that exist for lamivudine apply to emtricitabine.

Tenofovir

TDF, a nucleotide analogue, is one of the preferred first-line agents for HIV treatment and has proven efficacy against both wild-type and lamivudine-resistant HBV. Since it was first used for HIV, TDF has been more extensively studied in coinfected patients compared to most other agents. In a meta-analysis of patients with HIV/HBV coinfection, TDF suppressed HBV viral load to undetectable titers in approximately 90% of patients [46]. Tenofovir is available in 2 preparations: TDF and TAF. TDF has been reported to cause renal impairment as well as bone loss. TAF has shown less renal toxicity and less bone damage [40,47]. In 2016, TAF became available as part as 4 regimens: stand-alone TAF, elvitegravir-cobicistat-emtricitabine-TAF, rilpivirine-emtricitabine-TAF, and TAF-emtricitabine.

TDF and TAF both suppress HIV. Two large randomized trials of HBV monoinfection demonstrate that TAF is noninferior to TDF for the treatment of naïve and treatment-experienced patients [48,49].

Entecavir

Entecavir, a guanosine analogue, is a potent HBV DNA polymerase inhibitor that results in greater virologic suppression compared to lamivudine and retains activity against lamivudine-resistant HBV [50]. Importantly, entecavir shares some cross-resistance with lamivudine, so an entecavir dose of 1 mg daily is recommended in lamivudine-experienced patients compared to 0.5 mg daily in lamivudine-naïve patients. Entecavir requires dose reduction for patients with creatinine clearance less than 50 mL/min, although it is not associated with renal toxicity. A 1-log10 reduction in HIV RNA levels as well as emergence of M184V mutations on entecavir monotherapy has been reported [51,52]. M184V confers HIV resistance to lamivudine and emtricitabine. Therefore, entecavir should not be used as monotherapy in HIV-coinfected patients and/or patients with evidence of lamivudine-resistant HBV.

Combination Therapy

Recent updates in the guidelines recommend that since emtricitabine, lamivudine, TDF, and TAF are active against both viruses, patients with coinfection should start ART with a fixed-dose combination of TDF/emtricitabine or TAF/emtricitabine or the individual drug combination TDF plus lamivudine [53]. Most experts recommend the use of combination HBV therapy in patients on ART, particularly with lamivudine given the high rates of resistance.

• When should HBV treatment be started in patients with coinfection?

An ART regimen containing TDF (creatinine clearance > 50 mL/min) or TAF (creatinine clearance > 30 mL/min) with lamivudine or emtricitabine should be used in all HIV/HBV patients as soon as the infection is diagnosed. If TDF or TAF cannot be used, the alternate recommended regimen for HBV is entecavir plus a fully suppressive ART. In those with decreased renal function, entecavir should be adjusted to renal function [19].

Although control of viremia is feasible, clearance of infection as marked by loss of HBsAg and development of anti-HBs is unlikely to occur in the majority of patients. Therefore, the goals of treatment focus on prevention of chronic liver disease complications by suppressing viral replication, which can halt disease progression. A suggested algorithm for the management of coinfected patients is provided (Figure).

• What is the duration of therapy for hepatitis B?

Most patients with HIV/HBV coinfection will require lifelong treatment. All patients on HBV therapy as a part of ART should continue HBV therapy, regardless of seroconversion status. Also, patients should be educated and advised against self-discontinuation as it may trigger hepatitis exacerbations and/or hepatic failure.

Case Patient 3

Initial Presentation and History

Two months after starting treatment for HIV and chronic HBV infection, a 46-year-old Hispanic woman presents to clinic with jaundice and right upper quadrant (RUQ) pain. The patient was recently diagnosed with HIV infection and was naïve to treatment with ART. Her CD4 cell count was 50 cells/µL, and her HIV viral load was 743,000 copies/mL, with no baseline mutations on HIV genotype. The patient was also diagnosed with chronic HBV infection with positive HBsAg and HBeAg and negative HBc IgM serologies, as well as an HBV DNA level of 87 million IU/mL. Routine blood work revealed normal renal function and serum transaminases. The decision was made to start the patient on darunavir/ritonavir and TDF/emtricitabine. The patient was also started on sulfamethoxazole/trimethoprim and azithromycin for opportunistic infection prophylaxis.

Physical Examination and Laboratory Testing

Examination is remarkable for mild tenderness in the RUQ and icteric sclera. Laboratory testing demonstrates the following: AST, 1523 U/L; ALT, 795 U/L; albumin, 2.8 mg/dL; and total bilirubin, 3.5 mg/dL. Her CD4 count has increased to 565 cells/µL, and her HIV viral load is 4320 copies/mL. Results of repeat hepatitis serologies are as follows: HBsAg positive, anti-HBc IgM positive, and an HBV DNA level of 4.2 million IU/mL. Testing for hepatitis A, C, and D is negative, and RUQ sonogram reveals no gallstones.

• What monitoring should be done for coinfected patients on HBV therapy?

Monitoring

Providers should routinely monitor patients’ response to HIV/HBV therapy. Initially, all coinfected patients should have liver function tests and HBV DNA levels checked every 12 weeks on therapy. Frequent monitoring allows early detection of HBV drug resistance as well as drug-related hepatotoxicity. In HBeAg-positive coinfected patients who achieve HBV DNA suppression, HBeAg and anti-HBe testing should be performed every 6 to 12 months to assess for seroconversion. In HBeAg-negative patients, only HBV DNA and liver function tests are needed. HBV virologic failure is defined as a greater than 1-log10 rise in HBV DNA levels or development of viremia in a patient with a previously suppressed DNA level on therapy.

Typically, virologic failure results from either the development of drug resistance or abrupt withdrawal of active HBV therapy due to patient nonadherence or changes to the ART regimen. Virologic failure can result in a rise in serum aminotransferases as well as decompensation in patients with significant underlying liver disease. Due to this risk, providers must counsel patients about the importance of adherence to therapy and should continue medications active against HBV when making a change in ART regimens, unless HBV drug resistance dictates a change in HBV therapy.

• What is the likely cause of this patient’s hepatitis “flare”?

Several studies indicate that patients with HIV/HBV coinfection are at increased risk of drug-related hepatotoxicity and grade 4 liver enzyme elevations [54,55].The first 3 months after initiation of ART is a particularly vulnerable time for liver injury. The differential diagnosis for an acute hepatitis “flare” following the initiation of ART is broad and includes the following: development of HBV drug resistance [16]; withdrawal of HBV-active medications due to nonadherence [54]; ART-related hepatotoxicity; superimposed infection with HAV, HCV, or HDV; other opportunistic infections including cytomegalovirus and mycobacterium avium complex; or IRIS, resulting in an exaggerated cytotoxic response by the recovering immune system [56,57]. Complete evaluation is critical to distinguish between the possible causes.

In this case, several clues point toward HBV-related IRIS as the most likely cause for the hepatitis “flare.” A low pretreatment CD4 cell count with a rapid rise after initiation of ART is associated with a higher rate of IRIS [57]. Serologic testing and imaging excluded superinfection with another hepatotropic virus or biliary tract disease. Appropriate declines in HIV viral load and HBV DNA levels imply patient adherence to therapy and argue against the development of HBV drug resistance. Finally, the emergence of anti-HBc IgM positivity signals HBV reactivation, which is commonly seen in patients with HBV-related IRIS [57]. The preferred treatment for HBV-related IRIS involves continuation of therapy, frequently leading to normalization of aminotransferases and subsequent HBeAg seroconversion. Because IRIS usually manifests within the first 6 to 12 weeks after starting ART, liver enzymes should be monitored closely during this period.

• What health maintenance should be done for coinfected patients?

All patients with HIV/HBV coinfection should be monitored for evidence of portal hypertension or cirrhosis and, if these conditions exist, should undergo endoscopic screening for esophageal varices as well as evaluation of ascites and encephalopathy. Patients with HBV are at increased risk for the development of HCC even in the absence of cirrhosis. A recent study showed low rates of HCC screening in HIV/HBV patients by HIV providers [58]. Whether HIV coinfection potentiates HCC risk is uncertain, though coinfected patients present at younger ages and with more symptoms than HIV-negative comparators [59]. Other risk factors for HCC include HCV infection, alcohol abuse, diabetes, obesity, exposure to environmental toxins, and cirrhosis of any etiology (most commonly non-alcoholic fatty liver disease, primary sclerosing cholangitis, primary biliary cirrhosis and hemochromatosis) [60].

The American Association of Liver Diseases (AASLD) guidelines recommend hepatic ultrasound screening every 6 months in all patients with cirrhosis or chronic HBV who are at increased risk (Asian men over the age of 40 years, Asian women over the age of 50 years, African or North American blacks, and patients with family history of HCC) [61]. They should also be referred for an esophagogastroduodenoscopy to evaluate for esophageal varices. In addition, all HIV/HBV coinfected patients with decompensated liver disease should be evaluated for transplantation. HIV infection is not a contraindication for liver transplant with the use of ART. However, since transplantation does not cure HBV infection, post-transplant HBV immune globulin and HBV treatment are required. Contemporary data suggest comparable survival rates after transplant in coinfected patients compared to HBV-monoinfected patients [51].

Summary

Routine screening with HBsAg, anti-HBs, and anti-HBc serologies is recommended for all HIV-positive individuals. Patients without evidence of prior exposure or vaccination and those with isolated anti-HBc should be offered vaccination. HIV-positive adults should receive three or four 40 µg/mL doses of single agent vaccine depending on the recombinant vaccine type available. Anti-HBsAg titers should be checked 1 month after completion of the immunization series. If quantitative anti-HBsAg levels are < 10 IU/mL, patients should receive a second vaccine cycle.

Patients who test positive for HBsAg should be tested for HBeAg, anti-HBe, and HBV DNA levels and have AST and ALT levels checked as well. All patients with HIV/HBV coinfection should start treatment as soon as HIV infection is diagnosed. ART needs to include 2 drugs against HBV, and therefore a fixed-dose combination of TDF/emtricitabine or TAF/emtricitabine or the individual combination of TDF plus lamivudine should be used.

Coinfected patients on treatment should have liver function tests as well as HBV DNA every 12 weeks. In HBeAg-positive coinfected individuals who achieve HBV DNA suppression, HBeAg and anti-HBe testing should be performed every 6 to 12 months to assess for seroconversion. HBV virologic failure is defined as a greater than 1-log10 rise in HBV DNA levels or development of viremia in a patient with a previously suppressed DNA level on therapy. Those with virologic failure should be tested for HBV resistance thorough HBV genotype. Coinfected patients with cirrhosis should receive ultrasound screening every 6 months for evidence of HCC and esophagogastroduodenoscopy to evaluate for esophageal varices.

From Tampa General Hospital, Tampa, FL.

Abstract

• Objective: To decrease insertion-related catheter-associated urinary tract infections (CAUTIs) attributed to the emergency department (ED) as well as facility-wide within a large teaching hospital.
• Methods: Recommendations from the Agency for Healthcare Research and Quality (AHRQ) toolkit for reducing CAUTIs in hospital units were used to implement both technical and socioadaptive changes focused on prevention of insertion-related CAUTIs in the ED through a trial that required 2 licensed personnel for insertion of all urinary catheters. The process would include a safety time-out to confirm catheter appropriateness and review of the proper steps for insertion as a means to encompass and hardwire both the technical and socioadaptive aspects of the Comprehensive Unit-based Safety Project methodology into ED practice.
• Results: There was a 75% decrease in CAUTI rates following the intervention (P = 0.05). This reduction was sustained for at least 1 year following implementation.
• Conclusion: Using AHRQ recommendations to implement socioadaptive and technical changes through 2-person insertion of urinary catheters yielded a significant and sustainable decrease in insertion-related CAUTI rates and utilization of indwelling urinary catheters in the ED at Tampa General Hospital.

Key words: catheter-associated urinary tract infections; infection prevention; quality improvement; change model.

Each year an estimated 721,800 health care–associated infections occur in U.S. acute care hospitals, resulting in approximately 75,000 deaths [1]. Catheter-associated urinary tract infections (CAUTIs) account for an estimated 449,334 of health care–associated infections s annually [2]. The direct medical cost per CAUTI ranges from $749 to $1007, resulting in direct costs to U.S. facilities of over $340 million annually [2]. Although CAUTIs are one of the most common health care–associated infections, the literature has shown that following well established prevention guidelines can greatly reduce their incidence.

Since most health care–associated infections are preventable and cause unnecessary patient harm, there is pressure from regulatory bodies to prevent such events during a patient’s hospitalization. Prevention of CAUTIs is a Joint Commission National Patient Safety Goal, and as of 2008 the Centers for Medicare and Medicaid Services (CMS) does not reimburse hospitals for the cost of additional care as a result of a CAUTI. Additionally, facility CAUTI data is included in the CMS value-based purchasing program, which can withhold payments to hospitals based on performance, as well as the inpatient quality reporting program, which requires public reporting of CAUTI to receive a higher annual payment.

Even before the external pressures of regulatory bodies, Tampa General Hospital has strived to protect patients by preventing infections through implementing best practices via multidisciplinary committees to maximize impact. Tampa General Hospital, a private not-for-profit level 1 trauma center located in downtown Tampa, Florida, is a teaching facility affiliated with the University of South Florida Morsani College of Medicine. It is licensed for more than 1000 beds and serves 12 surrounding counties with a population in excess of 4 million.

Background

CAUTI data had been collected in all of the intensive care units at the hospital for several years, benchmarked against national unit-specific rates, with feedback provided to committees and the hospital board. However, in 2006, a multidisciplinary committee chaired by the chief operating officer known as Committee Targeting Zero (CTZ) was formed to review best practices and analyze all device-associated infection rates in an effort to reduce hospital-acquired infections. To target reduction of the CAUTI rate, a Foley stabilization device and renewed focus on hand hygiene were implemented, and CAUTI rates were reduced by over 50% by the end of 2007.

When CAUTI rates began to climb in 2008, additional interventions were implemented under the direction of CTZ, including a literature review for CAUTI prevention for any new or novel prevention strategies, reporting of each CAUTI to leadership of the attributed unit at the time of identification, ongoing surveillance of the appropriateness of indwelling urinary catheters at the unit level with feedback to CTZ, and mandatory education focused on infection of CAUTI and proper insertion for all staff inserting indwelling urinary catheters. Additionally, in 2009 an evaluation of an antibiotic-coated Foley catheter was implemented to further decrease rates, resulting in a statistically significant 42% reduction in the CAUTI rate as compared to 2008. Other prevention strategies instituted between 2010 and 2012 included increased availability of condom catheters, a closed system urine culture collection kit, and computer-based learning module for all staff inserting indwelling urinary catheters.

In 2013, the hospital included CAUTI prevention as part of a facility-wide initiative to decrease patient harm. A CAUTI committee led by senior leadership was convened to address CAUTI rates that exceeded national benchmarks. The multidisciplinary team began as a subcommittee of CTZ and was chaired by the chief nursing officer with the support of the chief operations officer and included representation from the infection prevention department and nursing unit leadership. After reviewing the Healthcare Infection Control Practices Advisory Committee’s (HICPAC) guideline for prevention of CAUTIs [3], the committee focused its efforts on appropriate indications for insertion and timely removal, aseptic insertion, and proper maintenance of indwelling urinary catheters.

The key accomplishments of the CAUTI committee during 2014 included development of a comprehensive genitourinary management policy, incorporation of CAUTI prevention into new employee orientation for all patient care staff, aseptic indwelling urinary catheter insertion competency check-off with return demonstration (teachback methodology) for all nursing staff, and reinforcement of insertion criteria and daily assessment for necessity with documentation of indications, and removal via nurse-driven protocol when necessary. Additionally, a requirement to document indications for ordering urine cultures and a pop-up reminder in the electronic medical record for patients with an indwelling urinary catheter requiring indications to continue, both targeted towards physicians and advanced practice providers, were implemented.

In conjunction with the technical changes, additional strategies were executed with the intent of facilitating a culture of patient safety and reinforcing the aforementioned technical changes. In 2014, the hospital implemented Franklin Covey’s “The Speed of Trust” methodology [4] and its associated 13 behaviors hospital-wide. Additionally, several of the inpatient units participated in a quality improvement project with either the Florida Hospital Engagement Network (HEN) [5] or the Agency for Healthcare Research and Quality (AHRQ) Comprehensive Unit-based Safety Program (CUSP) [6] national project. Physician engagement and education was accomplished through a white paper written by the infection prevention department, summarizing the current state of CAUTI within the facility and highlighting strategies to reduce infection, including evidence-based guidelines on ordering urine cultures.

In an attempt to target ongoing improvement strategies, CAUTIs were categorized as either insertion-related, occurring within 7 days of insertion, or maintenance-related, occurring greater than 7 days of insertion; the date of insertion was considered day 1. A review of the facility CAUTI data demonstrated that an opportunity to reduce insertion-related CAUTIs existed and a high volume of urinary catheters were inserted in the emergency department (ED). Therefore, ED leadership agreed to participate in the CUSP initiative for EDs beginning April 2014. The goals of the CUSP initiative include using best practices for CAUTI prevention through the implementation of both technical and socioadaptive changes.

Methods

CUSP Initiative

The CUSP initiative focuses specifically on improving processes for determining catheter appropriateness and promoting proper insertion techniques in addition to changes in culture to facilitate teamwork and communication amongst frontline staff and improve collaboration between the ED and inpatient units. To participate in the project, a multidisciplinary team that included ED leadership, infection prevention department, and nursing clinical quality and research specialists was established.

The team designed an intervention that required 2 licensed personnel for insertion of all urinary catheters. The process would include a safety time-out consisting of a pause before inserting the indwelling urinary catheter to confirm catheter appropriateness and review of the proper steps for insertion as a means to encompass and hardwire both the technical and socioadaptive aspects of the CUSP methodology into ED practice.

Rollout Using 4Es

January through March 2015 was the implementation period during which education and validation of practices were conducted. The 4Es model created by the Johns Hopkins University Quality and Safety Research Group was used to roll out the changes in practice to the ED staff; the 4Es are Engagement, Education, Execution, and Evaluation [7]. To engage staff, the scope of CAUTIs, including the implications to both patients and to the health care system as a whole, were presented from a local (hospital) and a national perspective. Education was achieved by outlining the new process in ED staff education sessions, as well as through handouts, emails, and during shift change huddles. The content included a checklist (Figure 1) staff would use to follow proper aseptic technique as well as reminders of the intent of the project.

The process was executed through the use of a safety time-out completed by the 2 personnel (nurses) involved in the procedure prior to insertion of an indwelling urinary catheter. The time-out consisted of reviewing the insertion criteria to determine appropriateness for placement and the proper steps for insertion per hospital policy. The catheter was then inserted by one person while the second was solely responsible to assure compliance with proper aseptic technique. The procedure was stopped if aseptic technique was compromised. The indications for insertion and/or maintaining the urinary catheter are based on the HICPAC guidelines [3] and include the following:

• Acute urinary retention/obstruction
• Urologic, urethral or extensive abdominal surgical procedure
• Critically ill patient with unstable vital signs and requires close urine output monitoring (ICU patient receiving aggressive diuretic therapy, vasopressor/inotropic therapy, paralytic therapy, aggressive fluid management or titrated vasoactive medications)
• Stage 3 or 4 sacral or perineal pressure ulcer in a patient with incontinence
• End of life comfort
• Prevention of further trauma due to a difficult insertion
• Prolonged immobility due to unstable spinal fracture or pelvic fracture and inability to use bedpan.

During the implementation period, a process measure was used to evaluate the rollout. The compliance rate of returned insertion checklists versus the total number of insertions was calculated weekly and tracked over time. Although compliance was low at first, through several Plan-Do-Study-Act (PDSA) cycles conducted on a weekly basis, compliance steadily increased during the implementation period. Staff were also kept abreast of the compliance rates and progress of the project with weekly email updates and periodically in daily huddles during shift change.

Rollout Using 4Es

In parallel to the CUSP framework, the ED leadership team discretely used 6 of “The Speed of Trust” behaviors most relevant to the project to help drive the new process including get better, practice accountability, keep commitments, clarify expectations, deliver results, and create transparency. Get better was used to motivate staff to action in order to deliver the highest quality of care to our patients. Practice accountability was exercised by having the staff sign the checklist used in the new process. Deliver results was supported by the timely feedback of data to frontline staff to show whether the goal was being met. Clarifying expectations was demonstrated through feedback from weekly PDSA rapid cycles and constant reinforcement that all insertions must involve 2 personnel. Keeping commitments was established with an agreement amongst the staff and leadership to keep patients safe and deliver high quality care. Creating transparency was exemplified by explaining the initiative clearly to each patient and their family and allowing for any questions.

Outcomes Measurement

During the post-intervention period, progress was evaluated using 2 outcome measures: the insertion-related CAUTI rate and the catheter utilization ratio. National Healthcare Safety Network (NHSN) 2014 and 2015 criteria was used to identify any CAUTI [8] and for the purposes of this project, the insertion-related CAUTI rate was defined as the number of CAUTIs occurring ≤ 7 days after insertion, with the date of insertion being day 1, per 1000 catheters inserted in the ED. The utilization ratio was calculated from the number of catheters inserted per patient ED visits. The insertion-related CAUTI rates for the pre- and post-intervention periods were compared after excluding 2014 yeast CAUTIs to adjust for changes in the 2015 National Healthcare Safety Network CAUTI criteria, which removed yeast as an organism for CAUTI. The utilization ratio was also calculated and compared between pre- and post-intervention periods. All statistical analysis was done using the NHSN statistics calculator.

Results

During the pre-intervention period (April–December 2014) there were 10 infections and 1450 catheters inserted, which equates to an insertion-related CAUTI rate of 6.9/1,000 catheters. In the post-intervention period (April–December 2015), there were 2 infections and 1180 catheters placed, or an insertion-related CAUTI rate of 1.7/1000 catheters (Table 1)—a 75% decrease from the pre-intervention rate (P = 0.05).

Additionally, the utilization ratio was calculated for 2014 and 2015 based on the number of catheter insertions per total patient ED visits in each year (Table 2). In 2014 the utilization ratio was 2.2 and in 2015 the utilization ratio was 1.7, representing a 23% reduction (P < 0.01).

Discussion

As highlighted in the AHRQ toolkit [5], the project confirmed that using both technical and socioadaptive methodologies yielded a significant and sustainable impact on CAUTIs and utilization of indwelling urinary catheters. Prior to initiating the project, a review of the literature did not show any previous studies involving the insertion of urinary catheters by 2 licensed personnel. Since then, an acute care facility published data demonstrating a sustainable 39% reduction of CAUTI rates in an inpatient post-surgical unit within 6 months after the implementation of 2-person urinary catheter insertion [9]. The facility had also done extensive education and training on the CAUTI prevention best-practices prior to implementing the new insertion practices.

A key measure of success in regards to implementing cultural and technical changes is the sustainability of the results yielded after implementation. According to the AHRQ CAUTI toolkit, several specific strategies are necessary to successfully sustain prevention efforts. Implementing changes in the ED at our hospital in alignment with the goal of creating a culture of safety, incorporating the changes into daily work flow, employing both technical and socioadaptive interventions, empowering staff to stop the procedure if there are any concerns, and monitoring and communicating outcomes all ensure that the changes in practice will be sustained. Additionally, there is an engaged interdisciplinary CAUTI committee that continues to meet regularly as well as required yearly computer-based education for all frontline staff, and a “Safety Day” education session for all newly hired nurses where competency is assessed and validated for proper insertion and maintenance of a urinary catheter.

Initially, barriers for implementation included limited staff to ensure the presence of 2 licensed personnel for every urinary catheter insertion, lack of ability to collect checklist data in the electronic medical record and run compliance reports, and availability of the checklists at the onset of implementation. The staffing limitation seemed to work in favor of meeting the goals of the project, as staff were less likely to insert indwelling urinary catheters for inappropriate indications. In regards to the checklists, the barriers identified via the PDSA rapid cycles included inadequate locations to obtain checklists for use during insertion and drop-off locations for checklists after use. To increase availability and convenience, brightly colored folders labeled “FOLEY!” containing the checklists were placed both on the outside of the supply management stations and on the doors exiting the supply rooms where indwelling urinary catheter kits were located. Rounds were made on these folders approximately 1 to 2 times per week to be sure they remained full. In addition, more locations for dropping off completed forms were placed at all nursing stations as opposed to a single drop off location.

A limitation of the project is that there are not established metrics for infection rates in any outpatient setting nor are there established criteria to differentiate between insertion- and maintenance-related infections. While the metrics were created for the purposes of the project, they are easily reproducible within other health care facilities to track infection rates associated with outpatient areas. Additionally, by ensuring indications are met and proper insertion occurs in ED patients, the overall hospital’s CAUTI infection rate and standardized infection ratio are impacted, which are comparable across facilities. The criteria for differentiating between insertion and maintenance related infections was established in an attempt to define where the biggest vulnerabilities were with insertion versus maintenance. Days from insertion to infection were tracked for all infections, and arbitrarily a 7-day cutoff was used to consider the infection potentially insertion-related, as no evidence has been published to define this previously.

The lessons learned both during implementation of the changes in practice and the impact it can have on infection rates are valuable. Moving forward, Tampa General Hospital plans to spread dual personnel indwelling urinary catheter insertion as a best practice, first targeting inpatient units identified with the highest number of insertion-related infections as well as high device utilization ratios.

From Tampa General Hospital, Tampa, FL.

Abstract

• Objective: To decrease insertion-related catheter-associated urinary tract infections (CAUTIs) attributed to the emergency department (ED) as well as facility-wide within a large teaching hospital.
• Methods: Recommendations from the Agency for Healthcare Research and Quality (AHRQ) toolkit for reducing CAUTIs in hospital units were used to implement both technical and socioadaptive changes focused on prevention of insertion-related CAUTIs in the ED through a trial that required 2 licensed personnel for insertion of all urinary catheters. The process would include a safety time-out to confirm catheter appropriateness and review of the proper steps for insertion as a means to encompass and hardwire both the technical and socioadaptive aspects of the Comprehensive Unit-based Safety Project methodology into ED practice.
• Results: There was a 75% decrease in CAUTI rates following the intervention (P = 0.05). This reduction was sustained for at least 1 year following implementation.
• Conclusion: Using AHRQ recommendations to implement socioadaptive and technical changes through 2-person insertion of urinary catheters yielded a significant and sustainable decrease in insertion-related CAUTI rates and utilization of indwelling urinary catheters in the ED at Tampa General Hospital.

Key words: catheter-associated urinary tract infections; infection prevention; quality improvement; change model.

Each year an estimated 721,800 health care–associated infections occur in U.S. acute care hospitals, resulting in approximately 75,000 deaths [1]. Catheter-associated urinary tract infections (CAUTIs) account for an estimated 449,334 of health care–associated infections s annually [2]. The direct medical cost per CAUTI ranges from $749 to $1007, resulting in direct costs to U.S. facilities of over $340 million annually [2]. Although CAUTIs are one of the most common health care–associated infections, the literature has shown that following well established prevention guidelines can greatly reduce their incidence.

Since most health care–associated infections are preventable and cause unnecessary patient harm, there is pressure from regulatory bodies to prevent such events during a patient’s hospitalization. Prevention of CAUTIs is a Joint Commission National Patient Safety Goal, and as of 2008 the Centers for Medicare and Medicaid Services (CMS) does not reimburse hospitals for the cost of additional care as a result of a CAUTI. Additionally, facility CAUTI data is included in the CMS value-based purchasing program, which can withhold payments to hospitals based on performance, as well as the inpatient quality reporting program, which requires public reporting of CAUTI to receive a higher annual payment.

Even before the external pressures of regulatory bodies, Tampa General Hospital has strived to protect patients by preventing infections through implementing best practices via multidisciplinary committees to maximize impact. Tampa General Hospital, a private not-for-profit level 1 trauma center located in downtown Tampa, Florida, is a teaching facility affiliated with the University of South Florida Morsani College of Medicine. It is licensed for more than 1000 beds and serves 12 surrounding counties with a population in excess of 4 million.

Background

CAUTI data had been collected in all of the intensive care units at the hospital for several years, benchmarked against national unit-specific rates, with feedback provided to committees and the hospital board. However, in 2006, a multidisciplinary committee chaired by the chief operating officer known as Committee Targeting Zero (CTZ) was formed to review best practices and analyze all device-associated infection rates in an effort to reduce hospital-acquired infections. To target reduction of the CAUTI rate, a Foley stabilization device and renewed focus on hand hygiene were implemented, and CAUTI rates were reduced by over 50% by the end of 2007.

When CAUTI rates began to climb in 2008, additional interventions were implemented under the direction of CTZ, including a literature review for CAUTI prevention for any new or novel prevention strategies, reporting of each CAUTI to leadership of the attributed unit at the time of identification, ongoing surveillance of the appropriateness of indwelling urinary catheters at the unit level with feedback to CTZ, and mandatory education focused on infection of CAUTI and proper insertion for all staff inserting indwelling urinary catheters. Additionally, in 2009 an evaluation of an antibiotic-coated Foley catheter was implemented to further decrease rates, resulting in a statistically significant 42% reduction in the CAUTI rate as compared to 2008. Other prevention strategies instituted between 2010 and 2012 included increased availability of condom catheters, a closed system urine culture collection kit, and computer-based learning module for all staff inserting indwelling urinary catheters.

In 2013, the hospital included CAUTI prevention as part of a facility-wide initiative to decrease patient harm. A CAUTI committee led by senior leadership was convened to address CAUTI rates that exceeded national benchmarks. The multidisciplinary team began as a subcommittee of CTZ and was chaired by the chief nursing officer with the support of the chief operations officer and included representation from the infection prevention department and nursing unit leadership. After reviewing the Healthcare Infection Control Practices Advisory Committee’s (HICPAC) guideline for prevention of CAUTIs [3], the committee focused its efforts on appropriate indications for insertion and timely removal, aseptic insertion, and proper maintenance of indwelling urinary catheters.

The key accomplishments of the CAUTI committee during 2014 included development of a comprehensive genitourinary management policy, incorporation of CAUTI prevention into new employee orientation for all patient care staff, aseptic indwelling urinary catheter insertion competency check-off with return demonstration (teachback methodology) for all nursing staff, and reinforcement of insertion criteria and daily assessment for necessity with documentation of indications, and removal via nurse-driven protocol when necessary. Additionally, a requirement to document indications for ordering urine cultures and a pop-up reminder in the electronic medical record for patients with an indwelling urinary catheter requiring indications to continue, both targeted towards physicians and advanced practice providers, were implemented.

In conjunction with the technical changes, additional strategies were executed with the intent of facilitating a culture of patient safety and reinforcing the aforementioned technical changes. In 2014, the hospital implemented Franklin Covey’s “The Speed of Trust” methodology [4] and its associated 13 behaviors hospital-wide. Additionally, several of the inpatient units participated in a quality improvement project with either the Florida Hospital Engagement Network (HEN) [5] or the Agency for Healthcare Research and Quality (AHRQ) Comprehensive Unit-based Safety Program (CUSP) [6] national project. Physician engagement and education was accomplished through a white paper written by the infection prevention department, summarizing the current state of CAUTI within the facility and highlighting strategies to reduce infection, including evidence-based guidelines on ordering urine cultures.

In an attempt to target ongoing improvement strategies, CAUTIs were categorized as either insertion-related, occurring within 7 days of insertion, or maintenance-related, occurring greater than 7 days of insertion; the date of insertion was considered day 1. A review of the facility CAUTI data demonstrated that an opportunity to reduce insertion-related CAUTIs existed and a high volume of urinary catheters were inserted in the emergency department (ED). Therefore, ED leadership agreed to participate in the CUSP initiative for EDs beginning April 2014. The goals of the CUSP initiative include using best practices for CAUTI prevention through the implementation of both technical and socioadaptive changes.

Methods

CUSP Initiative

The CUSP initiative focuses specifically on improving processes for determining catheter appropriateness and promoting proper insertion techniques in addition to changes in culture to facilitate teamwork and communication amongst frontline staff and improve collaboration between the ED and inpatient units. To participate in the project, a multidisciplinary team that included ED leadership, infection prevention department, and nursing clinical quality and research specialists was established.

The team designed an intervention that required 2 licensed personnel for insertion of all urinary catheters. The process would include a safety time-out consisting of a pause before inserting the indwelling urinary catheter to confirm catheter appropriateness and review of the proper steps for insertion as a means to encompass and hardwire both the technical and socioadaptive aspects of the CUSP methodology into ED practice.

Rollout Using 4Es

January through March 2015 was the implementation period during which education and validation of practices were conducted. The 4Es model created by the Johns Hopkins University Quality and Safety Research Group was used to roll out the changes in practice to the ED staff; the 4Es are Engagement, Education, Execution, and Evaluation [7]. To engage staff, the scope of CAUTIs, including the implications to both patients and to the health care system as a whole, were presented from a local (hospital) and a national perspective. Education was achieved by outlining the new process in ED staff education sessions, as well as through handouts, emails, and during shift change huddles. The content included a checklist (Figure 1) staff would use to follow proper aseptic technique as well as reminders of the intent of the project.

The process was executed through the use of a safety time-out completed by the 2 personnel (nurses) involved in the procedure prior to insertion of an indwelling urinary catheter. The time-out consisted of reviewing the insertion criteria to determine appropriateness for placement and the proper steps for insertion per hospital policy. The catheter was then inserted by one person while the second was solely responsible to assure compliance with proper aseptic technique. The procedure was stopped if aseptic technique was compromised. The indications for insertion and/or maintaining the urinary catheter are based on the HICPAC guidelines [3] and include the following:

• Acute urinary retention/obstruction
• Urologic, urethral or extensive abdominal surgical procedure
• Critically ill patient with unstable vital signs and requires close urine output monitoring (ICU patient receiving aggressive diuretic therapy, vasopressor/inotropic therapy, paralytic therapy, aggressive fluid management or titrated vasoactive medications)
• Stage 3 or 4 sacral or perineal pressure ulcer in a patient with incontinence
• End of life comfort
• Prevention of further trauma due to a difficult insertion
• Prolonged immobility due to unstable spinal fracture or pelvic fracture and inability to use bedpan.

During the implementation period, a process measure was used to evaluate the rollout. The compliance rate of returned insertion checklists versus the total number of insertions was calculated weekly and tracked over time. Although compliance was low at first, through several Plan-Do-Study-Act (PDSA) cycles conducted on a weekly basis, compliance steadily increased during the implementation period. Staff were also kept abreast of the compliance rates and progress of the project with weekly email updates and periodically in daily huddles during shift change.

Rollout Using 4Es

In parallel to the CUSP framework, the ED leadership team discretely used 6 of “The Speed of Trust” behaviors most relevant to the project to help drive the new process including get better, practice accountability, keep commitments, clarify expectations, deliver results, and create transparency. Get better was used to motivate staff to action in order to deliver the highest quality of care to our patients. Practice accountability was exercised by having the staff sign the checklist used in the new process. Deliver results was supported by the timely feedback of data to frontline staff to show whether the goal was being met. Clarifying expectations was demonstrated through feedback from weekly PDSA rapid cycles and constant reinforcement that all insertions must involve 2 personnel. Keeping commitments was established with an agreement amongst the staff and leadership to keep patients safe and deliver high quality care. Creating transparency was exemplified by explaining the initiative clearly to each patient and their family and allowing for any questions.

Outcomes Measurement

During the post-intervention period, progress was evaluated using 2 outcome measures: the insertion-related CAUTI rate and the catheter utilization ratio. National Healthcare Safety Network (NHSN) 2014 and 2015 criteria was used to identify any CAUTI [8] and for the purposes of this project, the insertion-related CAUTI rate was defined as the number of CAUTIs occurring ≤ 7 days after insertion, with the date of insertion being day 1, per 1000 catheters inserted in the ED. The utilization ratio was calculated from the number of catheters inserted per patient ED visits. The insertion-related CAUTI rates for the pre- and post-intervention periods were compared after excluding 2014 yeast CAUTIs to adjust for changes in the 2015 National Healthcare Safety Network CAUTI criteria, which removed yeast as an organism for CAUTI. The utilization ratio was also calculated and compared between pre- and post-intervention periods. All statistical analysis was done using the NHSN statistics calculator.

Results

During the pre-intervention period (April–December 2014) there were 10 infections and 1450 catheters inserted, which equates to an insertion-related CAUTI rate of 6.9/1,000 catheters. In the post-intervention period (April–December 2015), there were 2 infections and 1180 catheters placed, or an insertion-related CAUTI rate of 1.7/1000 catheters (Table 1)—a 75% decrease from the pre-intervention rate (P = 0.05).

Additionally, the utilization ratio was calculated for 2014 and 2015 based on the number of catheter insertions per total patient ED visits in each year (Table 2). In 2014 the utilization ratio was 2.2 and in 2015 the utilization ratio was 1.7, representing a 23% reduction (P < 0.01).

Discussion

As highlighted in the AHRQ toolkit [5], the project confirmed that using both technical and socioadaptive methodologies yielded a significant and sustainable impact on CAUTIs and utilization of indwelling urinary catheters. Prior to initiating the project, a review of the literature did not show any previous studies involving the insertion of urinary catheters by 2 licensed personnel. Since then, an acute care facility published data demonstrating a sustainable 39% reduction of CAUTI rates in an inpatient post-surgical unit within 6 months after the implementation of 2-person urinary catheter insertion [9]. The facility had also done extensive education and training on the CAUTI prevention best-practices prior to implementing the new insertion practices.

A key measure of success in regards to implementing cultural and technical changes is the sustainability of the results yielded after implementation. According to the AHRQ CAUTI toolkit, several specific strategies are necessary to successfully sustain prevention efforts. Implementing changes in the ED at our hospital in alignment with the goal of creating a culture of safety, incorporating the changes into daily work flow, employing both technical and socioadaptive interventions, empowering staff to stop the procedure if there are any concerns, and monitoring and communicating outcomes all ensure that the changes in practice will be sustained. Additionally, there is an engaged interdisciplinary CAUTI committee that continues to meet regularly as well as required yearly computer-based education for all frontline staff, and a “Safety Day” education session for all newly hired nurses where competency is assessed and validated for proper insertion and maintenance of a urinary catheter.

Initially, barriers for implementation included limited staff to ensure the presence of 2 licensed personnel for every urinary catheter insertion, lack of ability to collect checklist data in the electronic medical record and run compliance reports, and availability of the checklists at the onset of implementation. The staffing limitation seemed to work in favor of meeting the goals of the project, as staff were less likely to insert indwelling urinary catheters for inappropriate indications. In regards to the checklists, the barriers identified via the PDSA rapid cycles included inadequate locations to obtain checklists for use during insertion and drop-off locations for checklists after use. To increase availability and convenience, brightly colored folders labeled “FOLEY!” containing the checklists were placed both on the outside of the supply management stations and on the doors exiting the supply rooms where indwelling urinary catheter kits were located. Rounds were made on these folders approximately 1 to 2 times per week to be sure they remained full. In addition, more locations for dropping off completed forms were placed at all nursing stations as opposed to a single drop off location.

A limitation of the project is that there are not established metrics for infection rates in any outpatient setting nor are there established criteria to differentiate between insertion- and maintenance-related infections. While the metrics were created for the purposes of the project, they are easily reproducible within other health care facilities to track infection rates associated with outpatient areas. Additionally, by ensuring indications are met and proper insertion occurs in ED patients, the overall hospital’s CAUTI infection rate and standardized infection ratio are impacted, which are comparable across facilities. The criteria for differentiating between insertion and maintenance related infections was established in an attempt to define where the biggest vulnerabilities were with insertion versus maintenance. Days from insertion to infection were tracked for all infections, and arbitrarily a 7-day cutoff was used to consider the infection potentially insertion-related, as no evidence has been published to define this previously.

The lessons learned both during implementation of the changes in practice and the impact it can have on infection rates are valuable. Moving forward, Tampa General Hospital plans to spread dual personnel indwelling urinary catheter insertion as a best practice, first targeting inpatient units identified with the highest number of insertion-related infections as well as high device utilization ratios.

From Tampa General Hospital, Tampa, FL.

Abstract

• Objective: To decrease insertion-related catheter-associated urinary tract infections (CAUTIs) attributed to the emergency department (ED) as well as facility-wide within a large teaching hospital.
• Methods: Recommendations from the Agency for Healthcare Research and Quality (AHRQ) toolkit for reducing CAUTIs in hospital units were used to implement both technical and socioadaptive changes focused on prevention of insertion-related CAUTIs in the ED through a trial that required 2 licensed personnel for insertion of all urinary catheters. The process would include a safety time-out to confirm catheter appropriateness and review of the proper steps for insertion as a means to encompass and hardwire both the technical and socioadaptive aspects of the Comprehensive Unit-based Safety Project methodology into ED practice.
• Results: There was a 75% decrease in CAUTI rates following the intervention (P = 0.05). This reduction was sustained for at least 1 year following implementation.
• Conclusion: Using AHRQ recommendations to implement socioadaptive and technical changes through 2-person insertion of urinary catheters yielded a significant and sustainable decrease in insertion-related CAUTI rates and utilization of indwelling urinary catheters in the ED at Tampa General Hospital.

Key words: catheter-associated urinary tract infections; infection prevention; quality improvement; change model.

Each year an estimated 721,800 health care–associated infections occur in U.S. acute care hospitals, resulting in approximately 75,000 deaths [1]. Catheter-associated urinary tract infections (CAUTIs) account for an estimated 449,334 of health care–associated infections s annually [2]. The direct medical cost per CAUTI ranges from $749 to $1007, resulting in direct costs to U.S. facilities of over $340 million annually [2]. Although CAUTIs are one of the most common health care–associated infections, the literature has shown that following well established prevention guidelines can greatly reduce their incidence.

Since most health care–associated infections are preventable and cause unnecessary patient harm, there is pressure from regulatory bodies to prevent such events during a patient’s hospitalization. Prevention of CAUTIs is a Joint Commission National Patient Safety Goal, and as of 2008 the Centers for Medicare and Medicaid Services (CMS) does not reimburse hospitals for the cost of additional care as a result of a CAUTI. Additionally, facility CAUTI data is included in the CMS value-based purchasing program, which can withhold payments to hospitals based on performance, as well as the inpatient quality reporting program, which requires public reporting of CAUTI to receive a higher annual payment.

Even before the external pressures of regulatory bodies, Tampa General Hospital has strived to protect patients by preventing infections through implementing best practices via multidisciplinary committees to maximize impact. Tampa General Hospital, a private not-for-profit level 1 trauma center located in downtown Tampa, Florida, is a teaching facility affiliated with the University of South Florida Morsani College of Medicine. It is licensed for more than 1000 beds and serves 12 surrounding counties with a population in excess of 4 million.

Background

CAUTI data had been collected in all of the intensive care units at the hospital for several years, benchmarked against national unit-specific rates, with feedback provided to committees and the hospital board. However, in 2006, a multidisciplinary committee chaired by the chief operating officer known as Committee Targeting Zero (CTZ) was formed to review best practices and analyze all device-associated infection rates in an effort to reduce hospital-acquired infections. To target reduction of the CAUTI rate, a Foley stabilization device and renewed focus on hand hygiene were implemented, and CAUTI rates were reduced by over 50% by the end of 2007.

When CAUTI rates began to climb in 2008, additional interventions were implemented under the direction of CTZ, including a literature review for CAUTI prevention for any new or novel prevention strategies, reporting of each CAUTI to leadership of the attributed unit at the time of identification, ongoing surveillance of the appropriateness of indwelling urinary catheters at the unit level with feedback to CTZ, and mandatory education focused on infection of CAUTI and proper insertion for all staff inserting indwelling urinary catheters. Additionally, in 2009 an evaluation of an antibiotic-coated Foley catheter was implemented to further decrease rates, resulting in a statistically significant 42% reduction in the CAUTI rate as compared to 2008. Other prevention strategies instituted between 2010 and 2012 included increased availability of condom catheters, a closed system urine culture collection kit, and computer-based learning module for all staff inserting indwelling urinary catheters.

In 2013, the hospital included CAUTI prevention as part of a facility-wide initiative to decrease patient harm. A CAUTI committee led by senior leadership was convened to address CAUTI rates that exceeded national benchmarks. The multidisciplinary team began as a subcommittee of CTZ and was chaired by the chief nursing officer with the support of the chief operations officer and included representation from the infection prevention department and nursing unit leadership. After reviewing the Healthcare Infection Control Practices Advisory Committee’s (HICPAC) guideline for prevention of CAUTIs [3], the committee focused its efforts on appropriate indications for insertion and timely removal, aseptic insertion, and proper maintenance of indwelling urinary catheters.

The key accomplishments of the CAUTI committee during 2014 included development of a comprehensive genitourinary management policy, incorporation of CAUTI prevention into new employee orientation for all patient care staff, aseptic indwelling urinary catheter insertion competency check-off with return demonstration (teachback methodology) for all nursing staff, and reinforcement of insertion criteria and daily assessment for necessity with documentation of indications, and removal via nurse-driven protocol when necessary. Additionally, a requirement to document indications for ordering urine cultures and a pop-up reminder in the electronic medical record for patients with an indwelling urinary catheter requiring indications to continue, both targeted towards physicians and advanced practice providers, were implemented.

In conjunction with the technical changes, additional strategies were executed with the intent of facilitating a culture of patient safety and reinforcing the aforementioned technical changes. In 2014, the hospital implemented Franklin Covey’s “The Speed of Trust” methodology [4] and its associated 13 behaviors hospital-wide. Additionally, several of the inpatient units participated in a quality improvement project with either the Florida Hospital Engagement Network (HEN) [5] or the Agency for Healthcare Research and Quality (AHRQ) Comprehensive Unit-based Safety Program (CUSP) [6] national project. Physician engagement and education was accomplished through a white paper written by the infection prevention department, summarizing the current state of CAUTI within the facility and highlighting strategies to reduce infection, including evidence-based guidelines on ordering urine cultures.

In an attempt to target ongoing improvement strategies, CAUTIs were categorized as either insertion-related, occurring within 7 days of insertion, or maintenance-related, occurring greater than 7 days of insertion; the date of insertion was considered day 1. A review of the facility CAUTI data demonstrated that an opportunity to reduce insertion-related CAUTIs existed and a high volume of urinary catheters were inserted in the emergency department (ED). Therefore, ED leadership agreed to participate in the CUSP initiative for EDs beginning April 2014. The goals of the CUSP initiative include using best practices for CAUTI prevention through the implementation of both technical and socioadaptive changes.

Methods

CUSP Initiative

The CUSP initiative focuses specifically on improving processes for determining catheter appropriateness and promoting proper insertion techniques in addition to changes in culture to facilitate teamwork and communication amongst frontline staff and improve collaboration between the ED and inpatient units. To participate in the project, a multidisciplinary team that included ED leadership, infection prevention department, and nursing clinical quality and research specialists was established.

The team designed an intervention that required 2 licensed personnel for insertion of all urinary catheters. The process would include a safety time-out consisting of a pause before inserting the indwelling urinary catheter to confirm catheter appropriateness and review of the proper steps for insertion as a means to encompass and hardwire both the technical and socioadaptive aspects of the CUSP methodology into ED practice.

Rollout Using 4Es

January through March 2015 was the implementation period during which education and validation of practices were conducted. The 4Es model created by the Johns Hopkins University Quality and Safety Research Group was used to roll out the changes in practice to the ED staff; the 4Es are Engagement, Education, Execution, and Evaluation [7]. To engage staff, the scope of CAUTIs, including the implications to both patients and to the health care system as a whole, were presented from a local (hospital) and a national perspective. Education was achieved by outlining the new process in ED staff education sessions, as well as through handouts, emails, and during shift change huddles. The content included a checklist (Figure 1) staff would use to follow proper aseptic technique as well as reminders of the intent of the project.

The process was executed through the use of a safety time-out completed by the 2 personnel (nurses) involved in the procedure prior to insertion of an indwelling urinary catheter. The time-out consisted of reviewing the insertion criteria to determine appropriateness for placement and the proper steps for insertion per hospital policy. The catheter was then inserted by one person while the second was solely responsible to assure compliance with proper aseptic technique. The procedure was stopped if aseptic technique was compromised. The indications for insertion and/or maintaining the urinary catheter are based on the HICPAC guidelines [3] and include the following:

• Acute urinary retention/obstruction
• Urologic, urethral or extensive abdominal surgical procedure
• Critically ill patient with unstable vital signs and requires close urine output monitoring (ICU patient receiving aggressive diuretic therapy, vasopressor/inotropic therapy, paralytic therapy, aggressive fluid management or titrated vasoactive medications)
• Stage 3 or 4 sacral or perineal pressure ulcer in a patient with incontinence
• End of life comfort
• Prevention of further trauma due to a difficult insertion
• Prolonged immobility due to unstable spinal fracture or pelvic fracture and inability to use bedpan.

During the implementation period, a process measure was used to evaluate the rollout. The compliance rate of returned insertion checklists versus the total number of insertions was calculated weekly and tracked over time. Although compliance was low at first, through several Plan-Do-Study-Act (PDSA) cycles conducted on a weekly basis, compliance steadily increased during the implementation period. Staff were also kept abreast of the compliance rates and progress of the project with weekly email updates and periodically in daily huddles during shift change.

Rollout Using 4Es

In parallel to the CUSP framework, the ED leadership team discretely used 6 of “The Speed of Trust” behaviors most relevant to the project to help drive the new process including get better, practice accountability, keep commitments, clarify expectations, deliver results, and create transparency. Get better was used to motivate staff to action in order to deliver the highest quality of care to our patients. Practice accountability was exercised by having the staff sign the checklist used in the new process. Deliver results was supported by the timely feedback of data to frontline staff to show whether the goal was being met. Clarifying expectations was demonstrated through feedback from weekly PDSA rapid cycles and constant reinforcement that all insertions must involve 2 personnel. Keeping commitments was established with an agreement amongst the staff and leadership to keep patients safe and deliver high quality care. Creating transparency was exemplified by explaining the initiative clearly to each patient and their family and allowing for any questions.

Outcomes Measurement

During the post-intervention period, progress was evaluated using 2 outcome measures: the insertion-related CAUTI rate and the catheter utilization ratio. National Healthcare Safety Network (NHSN) 2014 and 2015 criteria was used to identify any CAUTI [8] and for the purposes of this project, the insertion-related CAUTI rate was defined as the number of CAUTIs occurring ≤ 7 days after insertion, with the date of insertion being day 1, per 1000 catheters inserted in the ED. The utilization ratio was calculated from the number of catheters inserted per patient ED visits. The insertion-related CAUTI rates for the pre- and post-intervention periods were compared after excluding 2014 yeast CAUTIs to adjust for changes in the 2015 National Healthcare Safety Network CAUTI criteria, which removed yeast as an organism for CAUTI. The utilization ratio was also calculated and compared between pre- and post-intervention periods. All statistical analysis was done using the NHSN statistics calculator.

Results

During the pre-intervention period (April–December 2014) there were 10 infections and 1450 catheters inserted, which equates to an insertion-related CAUTI rate of 6.9/1,000 catheters. In the post-intervention period (April–December 2015), there were 2 infections and 1180 catheters placed, or an insertion-related CAUTI rate of 1.7/1000 catheters (Table 1)—a 75% decrease from the pre-intervention rate (P = 0.05).

Additionally, the utilization ratio was calculated for 2014 and 2015 based on the number of catheter insertions per total patient ED visits in each year (Table 2). In 2014 the utilization ratio was 2.2 and in 2015 the utilization ratio was 1.7, representing a 23% reduction (P < 0.01).

Discussion

As highlighted in the AHRQ toolkit [5], the project confirmed that using both technical and socioadaptive methodologies yielded a significant and sustainable impact on CAUTIs and utilization of indwelling urinary catheters. Prior to initiating the project, a review of the literature did not show any previous studies involving the insertion of urinary catheters by 2 licensed personnel. Since then, an acute care facility published data demonstrating a sustainable 39% reduction of CAUTI rates in an inpatient post-surgical unit within 6 months after the implementation of 2-person urinary catheter insertion [9]. The facility had also done extensive education and training on the CAUTI prevention best-practices prior to implementing the new insertion practices.

A key measure of success in regards to implementing cultural and technical changes is the sustainability of the results yielded after implementation. According to the AHRQ CAUTI toolkit, several specific strategies are necessary to successfully sustain prevention efforts. Implementing changes in the ED at our hospital in alignment with the goal of creating a culture of safety, incorporating the changes into daily work flow, employing both technical and socioadaptive interventions, empowering staff to stop the procedure if there are any concerns, and monitoring and communicating outcomes all ensure that the changes in practice will be sustained. Additionally, there is an engaged interdisciplinary CAUTI committee that continues to meet regularly as well as required yearly computer-based education for all frontline staff, and a “Safety Day” education session for all newly hired nurses where competency is assessed and validated for proper insertion and maintenance of a urinary catheter.

Initially, barriers for implementation included limited staff to ensure the presence of 2 licensed personnel for every urinary catheter insertion, lack of ability to collect checklist data in the electronic medical record and run compliance reports, and availability of the checklists at the onset of implementation. The staffing limitation seemed to work in favor of meeting the goals of the project, as staff were less likely to insert indwelling urinary catheters for inappropriate indications. In regards to the checklists, the barriers identified via the PDSA rapid cycles included inadequate locations to obtain checklists for use during insertion and drop-off locations for checklists after use. To increase availability and convenience, brightly colored folders labeled “FOLEY!” containing the checklists were placed both on the outside of the supply management stations and on the doors exiting the supply rooms where indwelling urinary catheter kits were located. Rounds were made on these folders approximately 1 to 2 times per week to be sure they remained full. In addition, more locations for dropping off completed forms were placed at all nursing stations as opposed to a single drop off location.

A limitation of the project is that there are not established metrics for infection rates in any outpatient setting nor are there established criteria to differentiate between insertion- and maintenance-related infections. While the metrics were created for the purposes of the project, they are easily reproducible within other health care facilities to track infection rates associated with outpatient areas. Additionally, by ensuring indications are met and proper insertion occurs in ED patients, the overall hospital’s CAUTI infection rate and standardized infection ratio are impacted, which are comparable across facilities. The criteria for differentiating between insertion and maintenance related infections was established in an attempt to define where the biggest vulnerabilities were with insertion versus maintenance. Days from insertion to infection were tracked for all infections, and arbitrarily a 7-day cutoff was used to consider the infection potentially insertion-related, as no evidence has been published to define this previously.

The lessons learned both during implementation of the changes in practice and the impact it can have on infection rates are valuable. Moving forward, Tampa General Hospital plans to spread dual personnel indwelling urinary catheter insertion as a best practice, first targeting inpatient units identified with the highest number of insertion-related infections as well as high device utilization ratios.

SAN DIEGO – By standardizing antibiotic treatment for simple and uncomplicated staphylococcal bloodstream infections (BSI), an algorithm effectively shortens therapy and simplifies decision making, according to results of a multinational randomized trial.

“The data from the study confirm that the algorithm achieves more with less and verify that shorter antibiotic courses are sufficient,” reported Thomas L. Holland, MD, an infectious disease specialist at Duke University Hospital in Durham, N.C.

CDC/Janice Haney Carr

[email protected]

SAN DIEGO – By standardizing antibiotic treatment for simple and uncomplicated staphylococcal bloodstream infections (BSI), an algorithm effectively shortens therapy and simplifies decision making, according to results of a multinational randomized trial.

“The data from the study confirm that the algorithm achieves more with less and verify that shorter antibiotic courses are sufficient,” reported Thomas L. Holland, MD, an infectious disease specialist at Duke University Hospital in Durham, N.C.

CDC/Janice Haney Carr

[email protected]

SAN DIEGO – By standardizing antibiotic treatment for simple and uncomplicated staphylococcal bloodstream infections (BSI), an algorithm effectively shortens therapy and simplifies decision making, according to results of a multinational randomized trial.

“The data from the study confirm that the algorithm achieves more with less and verify that shorter antibiotic courses are sufficient,” reported Thomas L. Holland, MD, an infectious disease specialist at Duke University Hospital in Durham, N.C.

CDC/Janice Haney Carr

[email protected]

Poorer-performing hospitals have higher readmission rates than better-performing hospitals for patients with similar diagnoses, a study shows.

Lead author Harlan M. Krumholz, MD, of Yale University, New Haven, Conn., and his colleagues analyzed Centers for Medicare and Medicaid Services hospital-wide readmission data and divided data from July 2014 through June 2015 into two random samples. Researchers used the first sample to calculate the risk-standardized readmission rate within 30 days for each hospital and classified hospitals into performance quartiles, with a lower readmission rate indicating better performance. The second study sample included patients who had two admissions for similar diagnoses at different hospitals that occurred more than 1 month and less than 1 year apart. Researchers compared the observed readmission rates among patients who had been admitted to hospitals in different performance quartiles. The analysis included all discharges occurring from July 1, 2014, through June 30, 2015, from short-term acute care or critical access hospitals in the United States involving Medicare patients who were aged 65 years or older.

Copyright Kimberly Pack/Thinkstock

“This study addresses a persistent concern that national readmission measures may reflect differences in unmeasured factors rather than in hospital performance,” they said. “The findings suggest that hospital quality contributes at least in part to readmission rates, independent of patient factors. By studying patients who were admitted twice within 1 year with similar diagnoses to different hospitals, this study design was able to isolate hospital signals of performance while minimizing differences among the patients. In these cases, because the same patients had similar admissions at two hospitals, the characteristics of the patients, including their level of social disadvantage, level of education, or degree of underlying illness, were broadly the same. The alignment of the differences that we observed with the results of the CMS hospital-wide readmission measure also adds to evidence that the readmission measure classifies true differences in performance.”

Dr. Krumholz and seven coauthors reported receiving support from contracts with the Center for Medicare and Medicaid Services to develop and reevaluate performance measures that are used for public reporting.

[email protected]

On Twitter @legal_med

Poorer-performing hospitals have higher readmission rates than better-performing hospitals for patients with similar diagnoses, a study shows.

Lead author Harlan M. Krumholz, MD, of Yale University, New Haven, Conn., and his colleagues analyzed Centers for Medicare and Medicaid Services hospital-wide readmission data and divided data from July 2014 through June 2015 into two random samples. Researchers used the first sample to calculate the risk-standardized readmission rate within 30 days for each hospital and classified hospitals into performance quartiles, with a lower readmission rate indicating better performance. The second study sample included patients who had two admissions for similar diagnoses at different hospitals that occurred more than 1 month and less than 1 year apart. Researchers compared the observed readmission rates among patients who had been admitted to hospitals in different performance quartiles. The analysis included all discharges occurring from July 1, 2014, through June 30, 2015, from short-term acute care or critical access hospitals in the United States involving Medicare patients who were aged 65 years or older.

Copyright Kimberly Pack/Thinkstock

“This study addresses a persistent concern that national readmission measures may reflect differences in unmeasured factors rather than in hospital performance,” they said. “The findings suggest that hospital quality contributes at least in part to readmission rates, independent of patient factors. By studying patients who were admitted twice within 1 year with similar diagnoses to different hospitals, this study design was able to isolate hospital signals of performance while minimizing differences among the patients. In these cases, because the same patients had similar admissions at two hospitals, the characteristics of the patients, including their level of social disadvantage, level of education, or degree of underlying illness, were broadly the same. The alignment of the differences that we observed with the results of the CMS hospital-wide readmission measure also adds to evidence that the readmission measure classifies true differences in performance.”

Dr. Krumholz and seven coauthors reported receiving support from contracts with the Center for Medicare and Medicaid Services to develop and reevaluate performance measures that are used for public reporting.

[email protected]

On Twitter @legal_med

Poorer-performing hospitals have higher readmission rates than better-performing hospitals for patients with similar diagnoses, a study shows.

Lead author Harlan M. Krumholz, MD, of Yale University, New Haven, Conn., and his colleagues analyzed Centers for Medicare and Medicaid Services hospital-wide readmission data and divided data from July 2014 through June 2015 into two random samples. Researchers used the first sample to calculate the risk-standardized readmission rate within 30 days for each hospital and classified hospitals into performance quartiles, with a lower readmission rate indicating better performance. The second study sample included patients who had two admissions for similar diagnoses at different hospitals that occurred more than 1 month and less than 1 year apart. Researchers compared the observed readmission rates among patients who had been admitted to hospitals in different performance quartiles. The analysis included all discharges occurring from July 1, 2014, through June 30, 2015, from short-term acute care or critical access hospitals in the United States involving Medicare patients who were aged 65 years or older.

Copyright Kimberly Pack/Thinkstock

“This study addresses a persistent concern that national readmission measures may reflect differences in unmeasured factors rather than in hospital performance,” they said. “The findings suggest that hospital quality contributes at least in part to readmission rates, independent of patient factors. By studying patients who were admitted twice within 1 year with similar diagnoses to different hospitals, this study design was able to isolate hospital signals of performance while minimizing differences among the patients. In these cases, because the same patients had similar admissions at two hospitals, the characteristics of the patients, including their level of social disadvantage, level of education, or degree of underlying illness, were broadly the same. The alignment of the differences that we observed with the results of the CMS hospital-wide readmission measure also adds to evidence that the readmission measure classifies true differences in performance.”

Dr. Krumholz and seven coauthors reported receiving support from contracts with the Center for Medicare and Medicaid Services to develop and reevaluate performance measures that are used for public reporting.

[email protected]

On Twitter @legal_med

More than 40% of adults have either experienced a medical error or been involved in the care of someone who did, according to a recent national survey.

Specifically, 21% of American adults said that they have personally experienced a medical error and 31% said that they have been involved in the care of another person who experienced an error. The combined total, which includes some overlap, was 41% in the survey conducted by the Institute for Healthcare Improvement (IHI)/National Patient Safety Foundation (NPSF) and National Opinion Research Center (NORC), a nonpartisan research institution at the University of Chicago, .

Medical errors were defined for respondents as “mistakes [that] sometimes result in no harm, while other times they may result in additional or prolonged treatment, emotional distress, disability, or death,” investigators at IHI/NPSF and NORC said in their report.

A misdiagnosed medical problem was the most common type of medical error, reported by 59% of those with error experience. The next most common type of error was a mistake during a test, surgery, or treatment, which was mentioned by 46% of those with error experience, followed by a diagnosis that didn’t make sense (42%), lack of respect (39%), and incorrect instructions about follow-up care (29%), the IHI/HPSF and NORC report indicated.

Feelings of disrespect were more common among younger respondents: 46% of those aged 18-44 years said they were not treated with respect by a health care provider, compared with 34% of those aged 45 years and older. No differences in disrespect were seen with regard to socioeconomic status, health literacy, or English language proficiency. Those who spoke a language other than English at home, however, were more than twice as likely to get the wrong medication from a physician (34%) than were those who did not (15%), the report showed.

The survey, which had a sampling error of plus or minus 3.2 percentage points, was conducted between May 12, 2017, and June 26, 2017, and involved 2,536 respondents. It was conducted with support from Medtronic.

[email protected]

More than 40% of adults have either experienced a medical error or been involved in the care of someone who did, according to a recent national survey.

Specifically, 21% of American adults said that they have personally experienced a medical error and 31% said that they have been involved in the care of another person who experienced an error. The combined total, which includes some overlap, was 41% in the survey conducted by the Institute for Healthcare Improvement (IHI)/National Patient Safety Foundation (NPSF) and National Opinion Research Center (NORC), a nonpartisan research institution at the University of Chicago, .

Medical errors were defined for respondents as “mistakes [that] sometimes result in no harm, while other times they may result in additional or prolonged treatment, emotional distress, disability, or death,” investigators at IHI/NPSF and NORC said in their report.

A misdiagnosed medical problem was the most common type of medical error, reported by 59% of those with error experience. The next most common type of error was a mistake during a test, surgery, or treatment, which was mentioned by 46% of those with error experience, followed by a diagnosis that didn’t make sense (42%), lack of respect (39%), and incorrect instructions about follow-up care (29%), the IHI/HPSF and NORC report indicated.

Feelings of disrespect were more common among younger respondents: 46% of those aged 18-44 years said they were not treated with respect by a health care provider, compared with 34% of those aged 45 years and older. No differences in disrespect were seen with regard to socioeconomic status, health literacy, or English language proficiency. Those who spoke a language other than English at home, however, were more than twice as likely to get the wrong medication from a physician (34%) than were those who did not (15%), the report showed.

The survey, which had a sampling error of plus or minus 3.2 percentage points, was conducted between May 12, 2017, and June 26, 2017, and involved 2,536 respondents. It was conducted with support from Medtronic.

[email protected]

More than 40% of adults have either experienced a medical error or been involved in the care of someone who did, according to a recent national survey.

Specifically, 21% of American adults said that they have personally experienced a medical error and 31% said that they have been involved in the care of another person who experienced an error. The combined total, which includes some overlap, was 41% in the survey conducted by the Institute for Healthcare Improvement (IHI)/National Patient Safety Foundation (NPSF) and National Opinion Research Center (NORC), a nonpartisan research institution at the University of Chicago, .

Medical errors were defined for respondents as “mistakes [that] sometimes result in no harm, while other times they may result in additional or prolonged treatment, emotional distress, disability, or death,” investigators at IHI/NPSF and NORC said in their report.

A misdiagnosed medical problem was the most common type of medical error, reported by 59% of those with error experience. The next most common type of error was a mistake during a test, surgery, or treatment, which was mentioned by 46% of those with error experience, followed by a diagnosis that didn’t make sense (42%), lack of respect (39%), and incorrect instructions about follow-up care (29%), the IHI/HPSF and NORC report indicated.

Feelings of disrespect were more common among younger respondents: 46% of those aged 18-44 years said they were not treated with respect by a health care provider, compared with 34% of those aged 45 years and older. No differences in disrespect were seen with regard to socioeconomic status, health literacy, or English language proficiency. Those who spoke a language other than English at home, however, were more than twice as likely to get the wrong medication from a physician (34%) than were those who did not (15%), the report showed.

The survey, which had a sampling error of plus or minus 3.2 percentage points, was conducted between May 12, 2017, and June 26, 2017, and involved 2,536 respondents. It was conducted with support from Medtronic.

[email protected]

Visit the NAMS annual meetings website

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

Visit the NAMS annual meetings website

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

Visit the NAMS annual meetings website

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

After nearly 2 months of negotiations, key senators said on Oct. 17 that they have reached a bipartisan deal on a proposal intended to stabilize the Affordable Care Act’s insurance market, which has been rocked by recent actions by President Donald Trump.

Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.), respectively the chairman and the top Democrat of the Senate Health, Education, Labor, and Pensions Committee, negotiated the emerging deal. The milestone agreement, they said, would guarantee payment of cost-sharing reduction subsidies that help some policyholders with low incomes afford their deductibles and other out-of-pocket costs for 2 years, 2018 and 2019.

President Trump announced on Oct. 12 that he would stop funding the subsidies, which also have been the subject of a long-running lawsuit.

Even if it fails to become law, the deal marks a singular achievement that has been almost completely missing in Congress for the past 8 years – a bipartisan compromise on how to make the nation’s health insurance system work.

“This is an agreement I am proud to support,” Sen. Murray said on the Senate floor, “because of the message it sends about how to get things done.”

The proposal – which will require 60 votes to pass the Senate and agreement from a still-dubious House of Representatives – also would restore $110 million in ACA outreach funding cut by the Trump administration. That funding would help guide eligible individuals to sign up for coverage on the health insurance exchanges during the open enrollment period that runs from Nov. 1 to Dec. 15.

In exchange for those provisions, urged by Democrats and state officials, Republicans would win some changes to make it easier for states to apply for waivers that would let them experiment with alternative ways to provide and subsidize health insurance. The deal also would allow the sale of less comprehensive catastrophic plans in the health exchanges. Currently, such plans can be sold only to those under age 30 years.

On the Senate floor, Sen. Alexander said, “This agreement avoids chaos. I don’t know a Democrat or a Republican who benefits from chaos.”

Senate Majority Leader Mitch McConnell (R-Ky.) reserved judgment about the deal.

Both parties still have some major disagreements when it comes to health care, Senate Minority Leader Chuck Schumer (D-N.Y.) told reporters on Oct. 17, but “I think there’s a growing consensus that in the short term we need stability in the markets. So we’ve achieved stability if this agreement becomes law.”

More than 60 senators have already participated in the meetings that led to the deal, Sen. Alexander said on the Senate floor. But the path to passage in the House is uncertain – with many conservatives vehemently opposed to anything that could be construed as helping the ACA succeed.

Rep. Mark Walker (R-N.C.), chairman of the conservative Republican Study Committee, tweeted on Oct. 17: “The GOP should focus on repealing & replacing Obamacare, not trying to save it. This bailout is unacceptable.”

Both Sen. Murray and Sen. Alexander said that they were still struggling over language to make sure that if the cost-sharing payments are resumed, insurers would not receive a windfall by keeping both those payments and the higher premiums that many states are allowing in anticipation of the payments being ended.

“We want to make sure that the cost-sharing payments go to the benefit of consumers, not the insurance companies,” Sen. Alexander said.

President Trump, who as recently as Oct. 16 called the cost-sharing subsidies “a payoff” to insurance companies, took credit for the negotiations. “If I didn’t cut the CSRs, they wouldn’t be meeting,” he said. That was not, in fact, the case. The negotiations had picked up some weeks ago after being called off earlier in September while the Senate tried for one last-ditch repeal vote.

On Oct. 13, White House Budget Director Mick Mulvaney told Politico that the president would not allow a short-term fix, calling a restoration of the cost-sharing reduction funds “corporate welfare and bailouts for the insurance companies.”

But on Oct. 17 the president hailed the deal. “We think it’s going to not only save money, but give people much better health care with a very, very much smaller premium spike,” he told reporters.
 

Kaiser Health News is a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.

After nearly 2 months of negotiations, key senators said on Oct. 17 that they have reached a bipartisan deal on a proposal intended to stabilize the Affordable Care Act’s insurance market, which has been rocked by recent actions by President Donald Trump.

Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.), respectively the chairman and the top Democrat of the Senate Health, Education, Labor, and Pensions Committee, negotiated the emerging deal. The milestone agreement, they said, would guarantee payment of cost-sharing reduction subsidies that help some policyholders with low incomes afford their deductibles and other out-of-pocket costs for 2 years, 2018 and 2019.

President Trump announced on Oct. 12 that he would stop funding the subsidies, which also have been the subject of a long-running lawsuit.

Even if it fails to become law, the deal marks a singular achievement that has been almost completely missing in Congress for the past 8 years – a bipartisan compromise on how to make the nation’s health insurance system work.

“This is an agreement I am proud to support,” Sen. Murray said on the Senate floor, “because of the message it sends about how to get things done.”

The proposal – which will require 60 votes to pass the Senate and agreement from a still-dubious House of Representatives – also would restore $110 million in ACA outreach funding cut by the Trump administration. That funding would help guide eligible individuals to sign up for coverage on the health insurance exchanges during the open enrollment period that runs from Nov. 1 to Dec. 15.

In exchange for those provisions, urged by Democrats and state officials, Republicans would win some changes to make it easier for states to apply for waivers that would let them experiment with alternative ways to provide and subsidize health insurance. The deal also would allow the sale of less comprehensive catastrophic plans in the health exchanges. Currently, such plans can be sold only to those under age 30 years.

On the Senate floor, Sen. Alexander said, “This agreement avoids chaos. I don’t know a Democrat or a Republican who benefits from chaos.”

Senate Majority Leader Mitch McConnell (R-Ky.) reserved judgment about the deal.

Both parties still have some major disagreements when it comes to health care, Senate Minority Leader Chuck Schumer (D-N.Y.) told reporters on Oct. 17, but “I think there’s a growing consensus that in the short term we need stability in the markets. So we’ve achieved stability if this agreement becomes law.”

More than 60 senators have already participated in the meetings that led to the deal, Sen. Alexander said on the Senate floor. But the path to passage in the House is uncertain – with many conservatives vehemently opposed to anything that could be construed as helping the ACA succeed.

Rep. Mark Walker (R-N.C.), chairman of the conservative Republican Study Committee, tweeted on Oct. 17: “The GOP should focus on repealing & replacing Obamacare, not trying to save it. This bailout is unacceptable.”

Both Sen. Murray and Sen. Alexander said that they were still struggling over language to make sure that if the cost-sharing payments are resumed, insurers would not receive a windfall by keeping both those payments and the higher premiums that many states are allowing in anticipation of the payments being ended.

“We want to make sure that the cost-sharing payments go to the benefit of consumers, not the insurance companies,” Sen. Alexander said.

President Trump, who as recently as Oct. 16 called the cost-sharing subsidies “a payoff” to insurance companies, took credit for the negotiations. “If I didn’t cut the CSRs, they wouldn’t be meeting,” he said. That was not, in fact, the case. The negotiations had picked up some weeks ago after being called off earlier in September while the Senate tried for one last-ditch repeal vote.

On Oct. 13, White House Budget Director Mick Mulvaney told Politico that the president would not allow a short-term fix, calling a restoration of the cost-sharing reduction funds “corporate welfare and bailouts for the insurance companies.”

But on Oct. 17 the president hailed the deal. “We think it’s going to not only save money, but give people much better health care with a very, very much smaller premium spike,” he told reporters.
 

Kaiser Health News is a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.

After nearly 2 months of negotiations, key senators said on Oct. 17 that they have reached a bipartisan deal on a proposal intended to stabilize the Affordable Care Act’s insurance market, which has been rocked by recent actions by President Donald Trump.

Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.), respectively the chairman and the top Democrat of the Senate Health, Education, Labor, and Pensions Committee, negotiated the emerging deal. The milestone agreement, they said, would guarantee payment of cost-sharing reduction subsidies that help some policyholders with low incomes afford their deductibles and other out-of-pocket costs for 2 years, 2018 and 2019.

President Trump announced on Oct. 12 that he would stop funding the subsidies, which also have been the subject of a long-running lawsuit.

Even if it fails to become law, the deal marks a singular achievement that has been almost completely missing in Congress for the past 8 years – a bipartisan compromise on how to make the nation’s health insurance system work.

“This is an agreement I am proud to support,” Sen. Murray said on the Senate floor, “because of the message it sends about how to get things done.”

The proposal – which will require 60 votes to pass the Senate and agreement from a still-dubious House of Representatives – also would restore $110 million in ACA outreach funding cut by the Trump administration. That funding would help guide eligible individuals to sign up for coverage on the health insurance exchanges during the open enrollment period that runs from Nov. 1 to Dec. 15.

In exchange for those provisions, urged by Democrats and state officials, Republicans would win some changes to make it easier for states to apply for waivers that would let them experiment with alternative ways to provide and subsidize health insurance. The deal also would allow the sale of less comprehensive catastrophic plans in the health exchanges. Currently, such plans can be sold only to those under age 30 years.

On the Senate floor, Sen. Alexander said, “This agreement avoids chaos. I don’t know a Democrat or a Republican who benefits from chaos.”

Senate Majority Leader Mitch McConnell (R-Ky.) reserved judgment about the deal.

Both parties still have some major disagreements when it comes to health care, Senate Minority Leader Chuck Schumer (D-N.Y.) told reporters on Oct. 17, but “I think there’s a growing consensus that in the short term we need stability in the markets. So we’ve achieved stability if this agreement becomes law.”

More than 60 senators have already participated in the meetings that led to the deal, Sen. Alexander said on the Senate floor. But the path to passage in the House is uncertain – with many conservatives vehemently opposed to anything that could be construed as helping the ACA succeed.

Rep. Mark Walker (R-N.C.), chairman of the conservative Republican Study Committee, tweeted on Oct. 17: “The GOP should focus on repealing & replacing Obamacare, not trying to save it. This bailout is unacceptable.”

Both Sen. Murray and Sen. Alexander said that they were still struggling over language to make sure that if the cost-sharing payments are resumed, insurers would not receive a windfall by keeping both those payments and the higher premiums that many states are allowing in anticipation of the payments being ended.

“We want to make sure that the cost-sharing payments go to the benefit of consumers, not the insurance companies,” Sen. Alexander said.

President Trump, who as recently as Oct. 16 called the cost-sharing subsidies “a payoff” to insurance companies, took credit for the negotiations. “If I didn’t cut the CSRs, they wouldn’t be meeting,” he said. That was not, in fact, the case. The negotiations had picked up some weeks ago after being called off earlier in September while the Senate tried for one last-ditch repeal vote.

On Oct. 13, White House Budget Director Mick Mulvaney told Politico that the president would not allow a short-term fix, calling a restoration of the cost-sharing reduction funds “corporate welfare and bailouts for the insurance companies.”

But on Oct. 17 the president hailed the deal. “We think it’s going to not only save money, but give people much better health care with a very, very much smaller premium spike,” he told reporters.
 

Kaiser Health News is a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.

Older and younger patients benefited from varicose vein procedures, a finding that calls into question the use of compression therapy as the primary treatment for patients aged 65 years and older, according to the results of a prospectively maintained database study of all patients in the Vascular Quality Initiative Varicose Vein Registry–participating centers.

Procedures for varicose veins in 1,068 patients aged 65 years or older showed similar improvement in Clinical, Etiology, Anatomy, and Pathophysiology class and Venous Clinical Severity Score, compared with a group of 2,691 younger patients, according to a report published in Journal of Vascular Surgery: Venous and Lymphatic Disorders. Among patients younger than 65 years, 57.4% had an improvement, compared with 52% of patients aged 65 years or older.

copyright iStock /Thinkstock

[email protected]

Older and younger patients benefited from varicose vein procedures, a finding that calls into question the use of compression therapy as the primary treatment for patients aged 65 years and older, according to the results of a prospectively maintained database study of all patients in the Vascular Quality Initiative Varicose Vein Registry–participating centers.

Procedures for varicose veins in 1,068 patients aged 65 years or older showed similar improvement in Clinical, Etiology, Anatomy, and Pathophysiology class and Venous Clinical Severity Score, compared with a group of 2,691 younger patients, according to a report published in Journal of Vascular Surgery: Venous and Lymphatic Disorders. Among patients younger than 65 years, 57.4% had an improvement, compared with 52% of patients aged 65 years or older.

copyright iStock /Thinkstock

[email protected]

Older and younger patients benefited from varicose vein procedures, a finding that calls into question the use of compression therapy as the primary treatment for patients aged 65 years and older, according to the results of a prospectively maintained database study of all patients in the Vascular Quality Initiative Varicose Vein Registry–participating centers.

Procedures for varicose veins in 1,068 patients aged 65 years or older showed similar improvement in Clinical, Etiology, Anatomy, and Pathophysiology class and Venous Clinical Severity Score, compared with a group of 2,691 younger patients, according to a report published in Journal of Vascular Surgery: Venous and Lymphatic Disorders. Among patients younger than 65 years, 57.4% had an improvement, compared with 52% of patients aged 65 years or older.

copyright iStock /Thinkstock

[email protected]